34 results on '"Liberto J"'
Search Results
2. Pancreatic Cancer
- Author
-
Dobelbower, Ralph R., primary, Wagner, Steven M., additional, Fadell, Ronald J., additional, Howard, John M., additional, and DiDio, Liberto J. A., additional
- Published
- 1990
- Full Text
- View/download PDF
3. Multiethnic meta-analysis identifies ancestry-specific and cross-ancestry loci for pulmonary function
- Author
-
Wyss, A.B. (Annah B.), Sofer, T. (Tamar), Lee, M.K. (Mi Kyeong), Terzikhan, N. (Natalie), Nguyen, J.N. (Jennifer N.), Lahousse, L. (Lies), Latourelle, J.C. (Jeanne), Smith, A.V. (Albert), Bartz, T.M. (Traci M.), Feitosa, M.F. (Mary Furlan), Gao, W. (Wei), Ahluwalia, T.S. (Tarunveer Singh), Tang, W. (Wenbo), Oldmeadow, C. (Christopher), Duan, Q. (Qing), Jong, K. (Kim) de, Wojczynski, M.K. (Mary ), Wang, X.-Q. (Xin-Qun), Noordam, R. (Raymond), Hartwig, F.P. (Fernando Pires), Jackson, V.E. (Victoria E.), Wang, T. (Tianyuan), Obeidat, M. (Ma’en), Hobbs, B.D. (Brian D.), Huan, T. (Tianxiao), Gui, H. (Hongsheng), Parker, M.M. (Margaret M.), Hu, D. (Donglei), Mogil, L.S. (Lauren S.), Kichaev, G. (Gleb), Jin, J. (Jianping), Graff, M.J. (Maud J.L.), Harris, T.B. (Tamara), Kalhan, R. (Ravi), Heckbert, S.R. (Susan), Paternoster, L. (Lavinia), Burkart, K.M. (Kristin), Liu, Y. (YongMei), Holliday, E.G. (Elizabeth), Wilson, J.F. (James), Vonk, J.M. (Judith), Sanders, J.L. (Jason L.), Barr, R.G. (Graham), Mutsert, R. (Reneé) de, Menezes, A.M.B. (Ana Maria Baptista), Adams, H.H.H. (Hieab), Van Den Berge, M. (Maarten), Joehanes, R. (Roby), Levin, A.M. (Albert M.), Liberto, J. (Jennifer), Launer, L.J. (Lenore), Morrison, A.C. (Alanna), Sitlani, C.M. (Colleen), Celedón, J.C. (Juan C.), Kritchevsky, S.B. (Stephen), Scott, R.J. (Rodney J.), Christensen, K. (Kaare), Rotter, J.I. (Jerome I.), Bonten, T.N. (Tobias N.), Wehrmeister, F.C. (Fernando C.), Bossé, Y. (Yohan), Xiao, S. (Shujie), Oh, S. (Sam), Franceschini, N. (Nora), Brody, J.A. (Jennifer A.), Kaplan, R.C. (Robert), Lohman, K. (Kurt), McEvoy, M. (Mark), Province, M.A. (Mike), Rosendaal, F.R. (Frits), Taylor, K.D. (Kent), Nickle, D.C. (David C.), Williams, L.K. (L. Keoki), Burchard, E.G. (Esteban), Wheeler, H.E. (Heather), Sin, D.D. (Don D.), Gudnason, V. (Vilmundur), North, K.E. (Kari), Fornage, M. (Myriam), Psaty, B.M. (Bruce M.), Myers, R.H. (Richard), O’Connor, G. (George), Hansen, T. (Torben), Laurie, C.C. (Cathy C.), Cassano, P.A. (Patricia), Sung, J. (Joohon), Kim, W.J. (Woo Jin), Attia, J. (John), Lange, L.A. (Leslie), Boezen, H.M. (Marike), Thyagarajan, B. (Bharat), Rich, S.S. (Stephen), Mook-Kanamori, D.O. (Dennis O.), Horta, B.L. (Bernardo Lessa), Uitterlinden, A.G. (André), Im, H.K. (Hae Kyung), Cho, M.H. (Michael H.), Brusselle, G.G. (Guy), Gharib, S.A. (Sina), Dupuis, J. (Josée), Manichaikul, A. (Ani), London, S.J. (Stephanie J.), Wyss, A.B. (Annah B.), Sofer, T. (Tamar), Lee, M.K. (Mi Kyeong), Terzikhan, N. (Natalie), Nguyen, J.N. (Jennifer N.), Lahousse, L. (Lies), Latourelle, J.C. (Jeanne), Smith, A.V. (Albert), Bartz, T.M. (Traci M.), Feitosa, M.F. (Mary Furlan), Gao, W. (Wei), Ahluwalia, T.S. (Tarunveer Singh), Tang, W. (Wenbo), Oldmeadow, C. (Christopher), Duan, Q. (Qing), Jong, K. (Kim) de, Wojczynski, M.K. (Mary ), Wang, X.-Q. (Xin-Qun), Noordam, R. (Raymond), Hartwig, F.P. (Fernando Pires), Jackson, V.E. (Victoria E.), Wang, T. (Tianyuan), Obeidat, M. (Ma’en), Hobbs, B.D. (Brian D.), Huan, T. (Tianxiao), Gui, H. (Hongsheng), Parker, M.M. (Margaret M.), Hu, D. (Donglei), Mogil, L.S. (Lauren S.), Kichaev, G. (Gleb), Jin, J. (Jianping), Graff, M.J. (Maud J.L.), Harris, T.B. (Tamara), Kalhan, R. (Ravi), Heckbert, S.R. (Susan), Paternoster, L. (Lavinia), Burkart, K.M. (Kristin), Liu, Y. (YongMei), Holliday, E.G. (Elizabeth), Wilson, J.F. (James), Vonk, J.M. (Judith), Sanders, J.L. (Jason L.), Barr, R.G. (Graham), Mutsert, R. (Reneé) de, Menezes, A.M.B. (Ana Maria Baptista), Adams, H.H.H. (Hieab), Van Den Berge, M. (Maarten), Joehanes, R. (Roby), Levin, A.M. (Albert M.), Liberto, J. (Jennifer), Launer, L.J. (Lenore), Morrison, A.C. (Alanna), Sitlani, C.M. (Colleen), Celedón, J.C. (Juan C.), Kritchevsky, S.B. (Stephen), Scott, R.J. (Rodney J.), Christensen, K. (Kaare), Rotter, J.I. (Jerome I.), Bonten, T.N. (Tobias N.), Wehrmeister, F.C. (Fernando C.), Bossé, Y. (Yohan), Xiao, S. (Shujie), Oh, S. (Sam), Franceschini, N. (Nora), Brody, J.A. (Jennifer A.), Kaplan, R.C. (Robert), Lohman, K. (Kurt), McEvoy, M. (Mark), Province, M.A. (Mike), Rosendaal, F.R. (Frits), Taylor, K.D. (Kent), Nickle, D.C. (David C.), Williams, L.K. (L. Keoki), Burchard, E.G. (Esteban), Wheeler, H.E. (Heather), Sin, D.D. (Don D.), Gudnason, V. (Vilmundur), North, K.E. (Kari), Fornage, M. (Myriam), Psaty, B.M. (Bruce M.), Myers, R.H. (Richard), O’Connor, G. (George), Hansen, T. (Torben), Laurie, C.C. (Cathy C.), Cassano, P.A. (Patricia), Sung, J. (Joohon), Kim, W.J. (Woo Jin), Attia, J. (John), Lange, L.A. (Leslie), Boezen, H.M. (Marike), Thyagarajan, B. (Bharat), Rich, S.S. (Stephen), Mook-Kanamori, D.O. (Dennis O.), Horta, B.L. (Bernardo Lessa), Uitterlinden, A.G. (André), Im, H.K. (Hae Kyung), Cho, M.H. (Michael H.), Brusselle, G.G. (Guy), Gharib, S.A. (Sina), Dupuis, J. (Josée), Manichaikul, A. (Ani), and London, S.J. (Stephanie J.)
- Abstract
Nearly 100 loci have been identified for pulmonary function, almost exclusively in studies of European ancestry populations. We extend previous research by meta-analyzing genome-wide association studies of 1000 Genomes imputed variants in relation to pulmonary function in a multiethnic population of 90,715 individuals of European (N = 60,552), African (N = 8429), Asian (N = 9959), and Hispanic/Latino (N = 11,775) ethnicities. We identify over 50 additional loci at genome-wide significance in ancestry-specific or multiethnic meta-analyses. Using recent fine-mapping methods incorporating functional annotation, gene expression, and differences in linkage disequilibrium between ethnicities, we further shed light on potential causal variants and genes at known and newly identified loci. Several of the novel genes encode proteins with predicted or established drug targets, including KCNK2 and CDK12. Our study highlights the utility of multiethnic and integrative genomics approaches to extend existing knowledge of the genetics of lu
- Published
- 2018
- Full Text
- View/download PDF
4. Multiethnic meta-analysis identifies ancestry-specific and cross-ancestry loci for pulmonary function
- Author
-
Wyss, AB, Sofer, T, Lee, MK, Terzikhan, N, Nguyen, JN, Lahousse, L, Latourelle, JC, Smith, AV, Bartz, TM, Feitosa, MF, Gao, W, Ahluwalia, TS, Tang, W, Oldmeadow, C, Duan, Q, de Jong, K, Wojczynski, MK, Wang, X-Q, Noordam, R, Hartwig, FP, Jackson, VE, Wang, T, Obeidat, M, Hobbs, BD, Huan, T, Gui, H, Parker, MM, Hu, D, Mogil, LS, Kichaev, G, Jin, J, Graff, M, Harris, TB, Kalhan, R, Heckbert, SR, Paternoster, L, Burkart, KM, Liu, Y, Holliday, EG, Wilson, JG, Vonk, JM, Sanders, JL, Barr, RG, de Mutsert, R, Baptista Menezes, AM, Adams, HHH, van den Berge, M, Joehanes, R, Levin, AM, Liberto, J, Launer, LJ, Morrison, AC, Sitlani, CM, Celedon, JC, Kritchevsky, SB, Scott, RJ, Christensen, K, Rotter, JI, Bonten, TN, Wehrmeister, FC, Bosse, Y, Xiao, S, Oh, S, Franceschini, N, Brody, JA, Kaplan, RC, Lohman, K, McEvoy, M, Province, MA, Rosendaal, FR, Taylor, KD, Nickle, DC, Williams, LK, Burchard, EG, Wheeler, HE, Sin, DD, Gudnason, V, North, KE, Fornage, M, Psaty, BM, Myers, RH, O'Connor, G, Hansen, T, Laurie, CC, Cassano, PA, Sung, J, Kim, WJ, Attia, JR, Lange, L, Boezen, HM, Thyagarajan, B, Rich, SS, Mook-Kanamori, DO, Horta, BL, Uitterlinden, AG, Im, HK, Cho, MH, Brusselle, GG, Gharib, SA, Dupuis, J, Manichaikul, A, London, SJ, Wyss, AB, Sofer, T, Lee, MK, Terzikhan, N, Nguyen, JN, Lahousse, L, Latourelle, JC, Smith, AV, Bartz, TM, Feitosa, MF, Gao, W, Ahluwalia, TS, Tang, W, Oldmeadow, C, Duan, Q, de Jong, K, Wojczynski, MK, Wang, X-Q, Noordam, R, Hartwig, FP, Jackson, VE, Wang, T, Obeidat, M, Hobbs, BD, Huan, T, Gui, H, Parker, MM, Hu, D, Mogil, LS, Kichaev, G, Jin, J, Graff, M, Harris, TB, Kalhan, R, Heckbert, SR, Paternoster, L, Burkart, KM, Liu, Y, Holliday, EG, Wilson, JG, Vonk, JM, Sanders, JL, Barr, RG, de Mutsert, R, Baptista Menezes, AM, Adams, HHH, van den Berge, M, Joehanes, R, Levin, AM, Liberto, J, Launer, LJ, Morrison, AC, Sitlani, CM, Celedon, JC, Kritchevsky, SB, Scott, RJ, Christensen, K, Rotter, JI, Bonten, TN, Wehrmeister, FC, Bosse, Y, Xiao, S, Oh, S, Franceschini, N, Brody, JA, Kaplan, RC, Lohman, K, McEvoy, M, Province, MA, Rosendaal, FR, Taylor, KD, Nickle, DC, Williams, LK, Burchard, EG, Wheeler, HE, Sin, DD, Gudnason, V, North, KE, Fornage, M, Psaty, BM, Myers, RH, O'Connor, G, Hansen, T, Laurie, CC, Cassano, PA, Sung, J, Kim, WJ, Attia, JR, Lange, L, Boezen, HM, Thyagarajan, B, Rich, SS, Mook-Kanamori, DO, Horta, BL, Uitterlinden, AG, Im, HK, Cho, MH, Brusselle, GG, Gharib, SA, Dupuis, J, Manichaikul, A, and London, SJ
- Abstract
Nearly 100 loci have been identified for pulmonary function, almost exclusively in studies of European ancestry populations. We extend previous research by meta-analyzing genome-wide association studies of 1000 Genomes imputed variants in relation to pulmonary function in a multiethnic population of 90,715 individuals of European (N = 60,552), African (N = 8429), Asian (N = 9959), and Hispanic/Latino (N = 11,775) ethnicities. We identify over 50 additional loci at genome-wide significance in ancestry-specific or multiethnic meta-analyses. Using recent fine-mapping methods incorporating functional annotation, gene expression, and differences in linkage disequilibrium between ethnicities, we further shed light on potential causal variants and genes at known and newly identified loci. Several of the novel genes encode proteins with predicted or established drug targets, including KCNK2 and CDK12. Our study highlights the utility of multiethnic and integrative genomics approaches to extend existing knowledge of the genetics of lung function and clinical relevance of implicated loci.
- Published
- 2018
5. Prevalence and significance of fovea plana in patients with epiretinal membrane
- Author
-
Lejoyeux, R, Liberto, J, Bonnin, S, Le Mer, Y, Bruneau, S, and Tadayoni, R
- Abstract
Introduction Fovea plana is indicative of an immature inner retina, yet its association with epimacular membrane (ERM) remains unexplored. This study aims to investigate the prevalence of fovea plana in the contralateral eye of patients diagnosed with ERM.Methods A retrospective analysis was conducted on consecutive patients in a monocentric tertiary ophthalmic department between January and April 2021. The study included all patients referred for ERM, with dense optical coherence tomography (OCT) B-scans utilized to assess the incidence of fovea plana in the contralateral eye. Patients with bilateral ERM were excluded from the analysis.Results Out of 181 patients, 26 exhibited fovea plana in the contralateral eye, resulting in an incidence rate of 14.3%. Demographic characteristics, OCT patterns, and indications for surgery did not differ significantly between patients with and without fovea plana.Discussion The prevalence of fovea plana in patients with ERM did not exhibit a statistically significant increase compared to the reported incidence in patients undergoing preoperative cataract surgery.Conclusion In our cohort, the incidence of fovea plana in patients with ERM was determined to be 14.3%.
- Published
- 2024
- Full Text
- View/download PDF
6. Two-pion Bose-Einstein correlations in pp collisions at s = 900 GeV
- Author
-
Aamodt, K., Abel, 1 N., Abeysekara, 2 U., Abrahantes Quintana, 3 A., Abramyan, 4 A., Adamova´, 5 D., Aggarwal, 6 M. M., Aglieri Rinella, 7 G., Agocs, 8 A. G., Aguilar Salazar, 9 S., Ahammed, 10 Z., Ahmad, 11 A., Ahmad, 12 N., Ahn, 12 S. U., Akimoto, b. R., Akindinov, 14 A., Aleksandrov, 15 D., Alessandro, 16 B., Alfaro Molina, 17 R., Alici, 10 A., Avin˜a, 18 E. Almara´z., Alme, 10 J., Alt, 19 T., 2, Altini, c. V., Altinpinar, 20 S., Andrei, 21 C., Andronic, 22 A., Anelli, 21 G., Angelov, 8 V., Anson, c. C., Anticˇic´, 23 T., Antinori, 24 F., 8, Antinori, d. S., Antipin, 18 K., Anton´czyk, 25 D., Antonioli, 25 P., Anzo, 26 A., Aphecetche, 10 L., Appelsha¨user, 27 H., Arcelli, 25 S., Arceo, 18 R., Arend, 10 A., Armesto, 25 N., Arnaldi, 28 R., Aronsson, 17 T., Arsene, 29 I. C., 1, Asryan, e. A., Augustinus, 30 A., Averbeck, 8 R., Awes, 21 T. C., A¨ ysto¨, 31 J., Azmi, 32 M. D., Bablok, 12 S., Bach, 19 M., Badala`, 33 A., Baek, 34 Y. W., Bagnasco, b. S., Bailhache, 17 R., Bala, f. R., Baldisseri, 35 A., Baldit, 36 A., Ba´n, 37 J., Barbera, 38 R., Barnafo¨ldi, 39 G. G., Barnby, 9 L. S., Barret, 40 V., Bartke, 37 J., Barile, 41 F., Basile, 20 M., Basmanov, 18 V., Bastid, 42 N., Bathen, 37 B., Batigne, 43 G., Batyunya, 27 B., Baumann, 44 C., Bearden, f. I. G., Becker, 45 B., Belikov, g. I., Bellwied, 47 R., Belmont Moreno, 48 E., Belogianni, 10 A., Benhabib, 49 L., Beole, 27 S., Berceanu, 35 I., Bercuci, 22 A., Berdermann, h. E., Berdnikov, 21 Y., Betev, 50 L., Bhasin, 8 A., Bhati, 51 A. K., Bianchi, 7 L., Bianchi, 35 N., Bianchin, 52 C., Bielcˇı´k, 53 J., Bielcˇı´kova´, 54 J., Bilandzic, 6 A., Bimbot, 55 L., Biolcati, 56 E., Blanc, 35 A., Blanco, 37 F., Blanco, i. F., Blau, 57 D., Blume, 16 C., Boccioli, 25 M., Bock, 8 N., Bogdanov, 23 A., Bøggild, 58 H., Bogolyubsky, 45 M., Bohm, 59 J., Boldizsa´r, 60 L., Bombara, 9 M., Bombonati, 61 C., Bondila, j. M., Borel, 32 H., Borisov, 36 A., Bortolin, 62 C., Bose, k. S., Bosisio, Luciano, Bossu´, 64 F., Botje, 35 M., Bo¨ttger, 55 S., Bourdaud, 2 G., Boyer, 27 B., Braun, 56 M., Braun Munzinger, 30 P., 65, 21, Bravina, c. L., Bregant, Marco, Breitner, l. T., Bruckner, 2 G., Brun, 8 R., Bruna, 8 E., Bruno, 29 G. E., Budnikov, 20 D., Buesching, 42 H., Buncic, 25 P., Busch, 8 O., Buthelezi, 66 Z., Caffarri, 67 D., Cai, 53 X., Caines, 68 H., Calvo, 29 E., Camacho, 69 E., Camerini, Paolo, Campbell, 64 M., Canoa Roman, 8 V., Capitani, 8 G. P., Cara Romeo, 52 G., Carena, 26 F., Carena, 8. W., Carminati, 8 F., Casanova Dı´az, 8 A., Caselle, 52 M., Castillo Castellanos, 8 J., Castillo Hernandez, 36 J. F., Catanescu, 21 V., Cattaruzza, Enrico, Cavicchioli, 64 C., Cerello, 8 P., Chambert, 17 V., Chang, 56 B., Chapeland, 60 S., Charpy, 8 A., Charvet, 56 J. L., Chattopadhyay, 36 S., Chattopadhyay, 63 S., Cherney, 11 M., Cheshkov, 3 C., Cheynis, 8 B., Chiavassa, 71 E., Chibante Barroso, 35 V., Chinellato, 8 D. D., Chochula, 72 P., Choi, 8 K., Chojnacki, 73 M., Christakoglou, 74 P., Christensen, 74 C. H., Christiansen, 45 P., Chujo, 75 T., Chuman, 76 F., Cicalo, 77 C., Cifarelli, 46 L., Cindolo, 18 F., Cleymans, 26 J., Cobanoglu, 67 O., Coffin, 35 J. P., Coli, 47 S., Colla, 17 A., Conesa Balbastre, 8 G., Conesa del Valle, 52 Z., Conner, m. E. S., Constantin, 78 P., Contin, Giacomo, Contreras, j. J. G., Corrales Morales, 70 Y., Cormier, 35 T. M., Cortese, 48 P., Maldonado, 79 I. Corte´s., Cosentino, 80 M. R., Costa, 72 F., Cotallo, 8 M. E., Crescio, 57 E., Crochet, 70 P., Cuautle, 37 E., Cunqueiro, 81 L., Cussonneau, 52 J., Dainese, 27 A., Dalsgaard, 82 H. H., Danu, 45 A., Das, 83 I., Dash, 63 A., Dash, 84 S., de Barros, 84 G. O. V., De Caro, 85 A., de Cataldo, 86 G., de Cuveland, 87 J., De Falco, c. A., De Gaspari, 88 M., de Groot, 66 J., De Gruttola, 8 D., De Marco, 86 N., De Pasquale, 17 S., De Remigis, 86 R., de Rooij, 17 R., de Vaux, 74 G., Delagrange, 67 H., Delgado, 27 Y., Dellacasa, 69 G., Deloff, 79 A., Demanov, 89 V., De´nes, 42 E., Deppman, 9 A., D’Erasmo, 85 G., Derkach, 20 D., Devaux, 30 A., Di Bari, 37 D., Di Giglio, 20 C., Di Liberto, j. S., Di Mauro, 90 A., Di Nezza, 8 P., Dialinas, 52 M., Dı´az, 27 L., Dı´az, 81 R., Dietel, 32 T., Divia`, 43 R., Djuvsland, 8 Ø., Dobretsov, 19 V., Dobrin, 16 A., Dobrowolski, 75 T., Do¨nigus, 89 B., Domı´nguez, 21 I., Don, 81 D. M. M., Dordic, 91 O., Dubey, 1 A. K., Dubuisson, 11 J., Ducroux, 8 L., Dupieux, 71 P., Dutta Majumdar, 37 A. K., Dutta Majumdar, 63 M. R., Elia, 11 D., Emschermann, 87 D., Enokizono, n. A., Espagnon, 31 B., Estienne, 56 M., Esumi, 27 S., Evans, 76 D., Evrard, 40 S., Eyyubova, 8 G., Fabjan, 1 C. W., Fabris, o. D., Faivre, 82 J., Falchieri, 92 D., Fantoni, 18 A., Fasel, 52 M., Fateev, 21 O., Fearick, 44 R., Fedunov, 67 A., Fehlker, 44 D., Fekete, 19 V., Felea, 93 D., Fenton Olsen, 83 B., Feofilov, p. G., Ferna´ndez Te´llez, 30 A., Ferreiro, 80 E. G., Ferretti, 28 A., Ferretti, 35 R., Figueredo, q. M. A. S., Filchagin, 85 S., Fini, 42 R., Fionda, 87 F. M., Fiore, 20 E. M., Floris, 20 M., Fodor, j. Z., Foertsch, 9 S., Foka, 67 P., Fokin, 21 S., Formenti, 16 F., Fragiacomo, 8 E., Fragkiadakis, 94 M., Frankenfeld, 49 U., Frolov, 21 A., Fuchs, 95 U., Furano, 8 F., Furget, 8 C., Fusco Girard, 92 M., Gaardhøje, 86 J. J., Gadrat, 45 S., Gagliardi, 92 M., Gago, 35 A., Gallio, 69 M., Ganoti, 35 P., Ganti, 49 M. S., Garabatos, 11 C., Trapaga, 21 C. Garcı´a., Gebelein, 35 J., Gemme, 2 R., Germain, 79 M., Gheata, 27 A., Gheata, 8 M., Ghidini, 8 B., Ghosh, 20 P., Giraudo, 11 G., Giubellino, 17 P., Gladysz Dziadus, 17 E., Glasow, 41 R., Gla¨ssel, a. P., Glenn, 66 A., Go´mez Jime´nez, 96 R., Gonza´lez Santos, 97 H., Gonza´lez Trueba, 80 L. H., Gonza´lez Zamora, 10 P., Gorbunov, 57 S., Gorbunov, c. Y., Gotovac, 3 S., Gottschlag, 98 H., Grabski, 43 V., Grajcarek, 10 R., Grelli, 66 A., Grigoras, 74 A., Grigoras, 8 C., Grigoriev, 8 V., Grigoryan, 58 A., Grigoryan, 5 S., Grinyov, 44 B., Grion, 62 N., Gros, 94 P., Grosse Oetringhaus, 75 J. F., Grossiord, 8 J. Y., Grosso, Raffaele, Guber, 82 F., Guernane, 99 R., Guerra, 92 C., Guerzoni, 69 B., Gulbrandsen, 18 K., Gulkanyan, 45 H., Gunji, 5 T., Gupta, 14 A., Gupta, 51 R., Gustafsson, 51 H. A., Gutbrod, a. H., Haaland, 21 Ø., Hadjidakis, 19 C., Haiduc, 56 M., Hamagaki, 83 H., Hamar, 14 G., Hamblen, 9 J., Han, 100 B. H., Harris, 101 J. W., Hartig, 29 M., Harutyunyan, 25 A., Hasch, 5 D., Hasegan, 52 D., Hatzifotiadou, 83 D., Hayrapetyan, 26 A., Heide, 5 M., Heinz, 43 M., Helstrup, 29 H., Herghelegiu, 102 A., Herna´ndez, 22 C., Herrera Corral, 21 G., Herrmann, 70 N., Hetland, 66 K. F., Hicks, 102 B., Hiei, 29 A., Hille, 77 P. T., Hippolyte, r. B., Horaguchi, 47 T., Hori, s. Y., Hristov, 14 P., Hrˇivna´cˇova´, 8 I., 56 S., Hu, Huang, 103 M., Huber, 19 S., Humanic, 21 T. J., Hutter, 23 D., Hwang, 33 D. S., Ichou, 101 R., Ilkaev, 27 R., Ilkiv, 42 I., Inaba, 89 M., Innocenti, 76 P. G., Ippolitov, 8 M., Irfan, 16 M., Ivan, 12 C., Ivanov, 74 A., Ivanov, 30 M., Ivanov, 21 V., Iwasaki, 50 T., Jachołkowski, 77 A., Jacobs, 8 P., Jancˇurova´, 104 L., Jangal, 44 S., Janik, 47 R., Jena, 93 C., Jena, 84 S., Jirden, 105 L., Jones, 8 G. T., Jones, 40 P. G., Jovanovic´, 40 P., Jung, 40 H., Jung, 13 W., Jusko, 13 A., Kaidalov, 40 A. B., Kalcher, 15 S., Kalinˇa´k, c. P., Kalisky, 38 M., Kalliokoski, 43 T., Kalweit, 32 A., Kamal, 65 A., Kamermans, 12 R., Kanaki, 74 K., Kang, 19 E., Kang, 13 J. H., Kapitan, 60 J., Kaplin, 6 V., Kapusta, 58 S., Karavichev, 8 O., Karavicheva, 99 T., Karpechev, 99 E., Kazantsev, 99 A., Kebschull, 16 U., Keidel, 2 R., Khan, 78 M. M., Khan, 12 S. A., Khanzadeev, 11 A., Kharlov, 50 Y., Kikola, 59 D., Kileng, 106 B., Kim, 102 D. J., Kim, 32 D. S., Kim, 13 D. W., Kim, 13 H. N., Kim, 13 J., Kim, 59 J. H., Kim, 101 J. S., Kim, 13 M., Kim, 60 S. H., Kim, 13 S., Kim, 101 Y., Kirsch, 60 S., Kisel, 8 I., Kiselev, e. S., Kisiel, 15 A., Klay, j. J. L., Klein, 107 J., Klein Bo¨sing, 66 C., Kliemant, n. M., Klovning, 25 A., Kluge, 19 A., Knichel, 8 M. L., Kniege, 21 S., Koch, 25 K., Kolevatov, 66 R., Kolojvari, 1 A., Kondratiev, 30 V., Kondratyeva, 30 N., Konevskih, 58 A., Kornas´, 99 E., Kour, 41 R., Kowalski, 40 M., Kox, 41 S., Kozlov, 92 K., Kral, 16 J., Kra´lik, l. I., Kramer, 38 F., Kraus, 25 I., Kravcˇa´kova´, e. A., Krawutschke, 61 T., Krivda, 108 M., Krumbhorn, 40 D., Krus, 66 M., Kryshen, 54 E., Krzewicki, 50 M., Kucheriaev, 55 Y., Kuhn, 16 C., Kuijer, 47 P. G., Kumar, 55 L., Kumar, 7 N., Kupczak, 7 R., Kurashvili, 106 P., Kurepin, 89 A., Kurepin, 99 A. N., Kuryakin, 99 A., Kushpil, 42 S., Kushpil, 6 V., Kutouski, 6 M., Kvaerno, 44 H., Kweon, 1 M. J., Kwon, 66 Y., La Rocca, 60 P., Lackner, t. F., de Guevara, 8 P. Ladro´n., Lafage, 57 V., Lal, 56 C., Lara, 51 C., Larsen, 2 D. T., Laurenti, 19 G., Lazzeroni, 26 C., Le Bornec, 40 Y., Le Bris, 56 N., Lee, 27 H., Lee, 73 K. S., Lee, 13 S. C., Lefe`vre, 13 F., Lenhardt, 27 M., Leistam, 27 L., Lehnert, 8 J., Lenti, 25 V., Leo´n, 87 H., Monzo´n, 10 I. Leo´n., Vargas, 97 H. Leo´n., Le´vai, 25 P., 9 X., Li, 103 Y., Li, Lietava, 103 R., Lindal, 40 S., Lindenstruth, 1 V., Lippmann, c. C., Lisa, 8 M. A., Liu, 23 L., Loginov, 19 V., Lohn, 58 S., Lopez, 8 X., Lo´pez Noriega, 37 M., Lo´pez Ramı´rez, 56 R., Lo´pez Torres, 80 E., Løvhøiden, 4 G., Lozea Feijo Soares, 1 A., 85 S., Lu, Lunardon, 103 M., Luparello, 53 G., Luquin, 35 L., Lutz, 27 J. R., 47 K., Ma, 68 R., Ma, Madagodahettige Don, 29 D. M., Maevskaya, 91 A., Mager, 99 M., Mahapatra, j. D. P., Maire, 84 A., Makhlyueva, 47 I., Mal’Kevich, 8 D., Malaev, 15 M., Malagalage, 50 K. J., Maldonado Cervantes, 3 I., Malek, 81 M., Malinina, 56 L., Malkiewicz, u. T., Malzacher, 32 P., Mamonov, 21 A., Manceau, 42 L., Mangotra, 37 L., Manko, 51 V., Manso, 16 F., Manzari, 37 V., Mao, 87 Y., Maresˇ, v. J., Margagliotti, Giacomo, Margotti, 64 A., Marı´n, 26 A., Martashvili, 21 I., Martinengo, 100 P., Martı´nez Herna´ndez, 8 M. I., Martı´nez Davalos, 80 A., Martı´nez Garcı´a, 10 G., Maruyama, 27 Y., Marzari Chiesa, 77 A., Masciocchi, 35 S., Masera, 21 M., Masetti, 35 M., Masoni, 18 A., Massacrier, 46 L., Mastromarco, 71 M., Mastroserio, 87 A., Matthews, j. Z. L., Matyja, 40 A., Mayani, w. D., Mazza, 81 G., Mazzoni, 17 M. A., Meddi, 90 F., Menchaca Rocha, 110 A., Mendez Lorenzo, 10 P., Meoni, 8 M., Mercado Pe´rez, 8 J., Mereu, 66 P., Miake, 17 Y., Michalon, 76 A., Miftakhov, 47 N., Milano, 50 L., Milosevic, 35 J., Minafra, 1 F., Mischke, 20 A., Mis´kowiec, 74 D., Mitu, 21 C., Mizoguchi, 83 K., Mlynarz, 77 J., Mohanty, 48 B., Molnar, 11 L., 9, Mondal, j. M. M., Zetina, 11 L. Montan˜o., Monteno, x. M., Montes, 17 E., Morando, 57 M., Moretto, 53 S., Morsch, 53 A., Moukhanova, 8 T., Muccifora, 16 V., Mudnic, 52 E., Muhuri, 98 S., Mu¨ ller, 11 H., Munhoz, 8 M. G., Munoz, 85 J., Musa, 80 L., Musso, 8 A., Nandi, 17 B. K., Nania, 105 R., Nappi, 26 E., Navach, 87 F., Navin, 20 S., Nayak, 40 T. K., Nazarenko, 11 S., Nazarov, 42 G., Nedosekin, 42 A., Nendaz, 15 F., Newby, 71 J., Nianine, 96 A., Nicassio, 16 M., Nielsen, j. B. S., Nikolaev, 45 S., Nikolic, 16 V., Nikulin, 24 S., Nikulin, 16 V., Nilsen, 50 B. S., Nilsson, 3 M. S., Noferini, 1 F., Nomokonov, 26 P., Nooren, 44 G., Novitzky, 74 N., Nyatha, 32 A., Nygaard, 105 C., Nyiri, 45 A., Nystrand, 1 J., Ochirov, 19 A., Odyniec, 30 G., Oeschler, 104 H., Oinonen, 65 M., Okada, 32 K., Okada, 14 Y., Oldenburg, 77 M., Oleniacz, 8 J., Oppedisano, 106 C., Orsini, 17 F., Ortiz Velasquez, 36 A., Ortona, 81 G., Oskarsson, 35 A., Osmic, 75 F., O¨ sterman, 8 L., Ostrowski, 75 P., Otterlund, 106 I., Otwinowski, 75 J., Øvrebekk, 21 G., Oyama, 19 K., Ozawa, 66 K., Pachmayer, 14 Y., Pachr, 66 M., Padilla, 54 F., Pagano, 35 P., Paic´, 86 G., Painke, 81 F., Pajares, 2 C., Pal, 28 S., Pal, y. S. K., Palaha, 11 A., Palmeri, 40 A., Panse, 34 R., Papikyan, 2 V., Pappalardo, 5 G. S., Park, 34 W. J., Pastircˇa´k, 21 B., Pastore, 38 C., Paticchio, 87 V., Pavlinov, 87 A., Pawlak, 48 T., Peitzmann, 106 T., Pepato, 74 A., Pereira, 82 H., Peressounko, 36 D., Pe´rez, 16 C., Perini, 69 D., Perrino, 8 D., Peryt, j. W., Peschek, 106 J., Pesci, c. A., Peskov, 26 V., Pestov, j. Y., Peters, 95 A. J., Petra´cˇek, 8 V., Petridis, 54 A., Petris, a. M., Petrov, 22 P., Petrovici, 40 M., Petta, 22 C., Peyre´, 39 J., Piano, Stefano, Piccotti, 94 A., Pikna, 17 M., Pillot, 93 P., Pinazza, 27 O., Pinsky, j. L., Pitz, 91 N., Piuz, 25 F., Platt, 8 R., Płoskon´, 40 M., Pluta, 104 J., Pocheptsov, 106 T., Pochybova, z. S., Podesta Lerma, 9 P. L. M., Poggio, 97 F., Poghosyan, 35 M. G., Pola´k, 35 K., Polichtchouk, 109 B., Polozov, 59 P., Polyakov, 15 V., Pommeresch, 50 B., Pop, 19 A., Posa, 22 F., Pospı´sˇil, 20 V., Potukuchi, 54 B., Pouthas, 51 J., Prasad, 56 S. K., Preghenella, 11 R., Prino, t. F., Pruneau, 17 C. A., Pshenichnov, 48 I., Puddu, 99 G., Pujahari, 88 P., Pulvirenti, 105 A., Punin, 39 A., Punin, 42 V., Putisˇ, 42 M., Putschke, 61 J., Quercigh, 29 E., Rachevski, 8 A., Rademakers, 94 A., Radomski, 8 S., Ra¨iha¨, 66 T. S., Rak, 32 J., Rakotozafindrabe, 32 A., Ramello, 36 L., Ramı´rez Reyes, 79 A., Rammler, 70 M., Raniwala, 43 R., Raniwala, 111 S., Ra¨sa¨nen, 111 S. S., Rashevskaya, 32 I., Rath, 94 S., Read, 84 K. F., Real, 100 J. S., Redlich, 92 K., Renfordt, aa R., Reolon, 25 A. R., Reshetin, 52 A., Rettig, 99 F., Revol, c. J. P., Reygers, 8 K., Ricaud, bb H., Riccati, 65 L., Ricci, 17 R. A., Richter, 112 M., Riedler, 19 P., Riegler, 8. W., Riggi, 8 F., Rivetti, 39 A., Rodriguez Cahuantzi, 17 M., Røed, 80 K., Ro¨hrich, 102 D., Roma´n Lo´pez, cc S., Romita, 80 R., Ronchetti, e. F., Rosinsky´, 52 P., Rosnet, 8 P., Rossegger, 37 S., Rossi, 8 A., Roukoutakis, dd F., Rousseau, ee S., Roy, 56 C., Roy, m. P., Rubio Montero, 63 A. J., Rui, Rinaldo, Rusanov, 64 I., Russo, 66 G., Ryabinkin, 86 E., Rybicki, 16 A., Sadovsky, 41 S., Afarˇı´k, 59 K. S. ˇ., Sahoo, 8 R., Saini, 53 J., Saiz, 11 P., Sakata, 8 D., Salgado, 76 C. A., Salgueiro Domingues da Silva, 28 R., Salur, 8 S., Samanta, 104 T., Sambyal, 11 S., Samsonov, 51 V., A´ndor, 50 L. S. ˇ., Sandoval, 38 A., Sano, 10 M., Sano, 76 S., Santo, 14 R., Santoro, 43 R., Sarkamo, 20 J., Saturnini, 32 P., Scapparone, 37 E., Scarlassara, 26 F., Scharenberg, 53 R. P., Schiaua, 113 C., Schicker, 22 R., Schindler, 66 H., Schmidt, 8 C., Schmidt, 21 H. R., Schossmaier, 21 K., Schreiner, 8 S., Schuchmann, 8 S., Schukraft, 25 J., Schutz, 8 Y., Schwarz, 27 K., Schweda, 21 K., Scioli, 66 G., Scomparin, 18 E., Scott, 17 P. A., Segato, 40 G., Semenov, 53 D., Senyukov, 30 S., Seo, 79 J., Serci, 13 S., Serkin, 88 L., Serradilla, 81 E., Sevcenco, 57 A., Sgura, 83 I., Shabratova, 20 G., Shahoyan, 44 R., Sharkov, 8 G., Sharma, 15 N., Sharma, 7 S., Shigaki, 51 K., Shimomura, 77 M., Shtejer, 76 K., Sibiriak, 4 Y., Siciliano, 16 M., Sicking, 35 E., Siddi, ff E., Siemiarczuk, 46 T., Silenzi, 89 A., Silvermyr, 18 D., Simili, 31 E., Simonetti, 74 G., Singaraju, j. R., Singh, 11 R., Singhal, 51 V., Sinha, 11 B. C., Sinha, 11 T., Sitar, 63 B., Sitta, 93 M., Skaali, 79 T. B., Skjerdal, 1 K., Smakal, 19 R., Smirnov, 54 N., Snellings, 29 R., Snow, 55 H., Søgaard, 40 C., Soloviev, 45 A., Soltveit, 59 H. K., Soltz, 66 R., Sommer, 96 W., Son, 25 C. W., Son, 73 H., Song, 101 M., Soos, 60 C., Soramel, 8 F., Soyk, 53 D., Spyropoulou Stassinaki, 21 M., Srivastava, 49 B. K., Stachel, 113 J., Staley, 66 F., Stan, 36 E., Stefanek, 83 G., Stefanini, 89 G., Steinbeck, 8 T., Stenlund, c. E., Steyn, 75 G., Stocco, 67 D., Stock, w. R., Stolpovsky, 25 P., Strmen, 59 P., Suaide, 93 A. A. P., Subieta Va´squez, 85 M. A., Sugitate, 35 T., Suire, 77 C., Umbera, 56 M. S. ˇ., Susa, 6 T., Swoboda, 24 D., Symons, 8 J., Szanto de Toledo, 104 A., Szarka, 85 I., Szostak, 93 A., Szuba, 46 M., Tadel, 106 M., Tagridis, 8 C., Takahara, 49 A., Takahashi, 14 J., Tanabe, 72 R., Tapia Takaki, 76 J. D., Taureg, 56 H., Tauro, 8 A., Tavlet, 8 M., Tejeda Mun˜oz, 8 G., Telesca, 80 A., Terrevoli, 8 C., Tha¨der, 20 J., Tieulent, c. R., Tlusty, 71 D., Toia, 54 A., Tolyhy, 8 T., Torcato de Matos, 9 C., Torii, 8 H., Torralba, 77 G., Toscano, 2 L., Tosello, 17 F., Tournaire, 17 A., Traczyk, gg T., Tribedy, 106 P., Tro¨ger, 11 G., Truesdale, 2 D., Trzaska, 23 W. H., Tsiledakis, 32 G., Tsilis, 66 E., Tsuji, 49 T., Tumkin, 14 A., Turrisi, 42 R., Turvey, 82 A., Tveter, 3 T. S., Tydesjo¨, 1 H., Tywoniuk, 8 K., Ulery, 1 J., Ullaland, 25 K., Uras, 19 A., Urba´n, 88 J., Urciuoli, 61 G. M., Usai, 90 G. L., Vacchi, 88 A., Vala, 94 M., Valencia Palomo, hh L., Vallero, 10 S., van der Kolk, 66 N., Vande Vyvre, 55 P., van Leeuwen, 8 M., Vannucci, 74 L., Vargas, 112 A., Varma, 80 R., Vasiliev, 105 A., Vassiliev, 16 I., Vasileiou, ee M., Vechernin, 49 V., Venaruzzo, Massimo, Vercellin, 64 E., Vergara, 35 S., Vernet, 80 R., Verweij, ii M., Vetlitskiy, 74 I., Vickovic, 15 L., Viesti, 98 G., Vikhlyantsev, 53 O., Vilakazi, 42 Z., Villalobos Baillie, 67 O., Vinogradov, 40 A., Vinogradov, 16 L., Vinogradov, 30 Y., Virgili, 42 T., Viyogi, 86 Y. P., Vodopianov, 11 A., Voloshin, 44 K., Voloshin, 15 S., Volpe, 48 G., von Haller, 20 B., Vranic, 8 D., Vrla´kova´, 21 J., Vulpescu, 61 B., Wagner, 37 B., Wagner, 19 V., Wallet, 54 L., Wan, 8 R., Wang, m. D., Wang, 68 Y., Wang, 66 Y., Watanabe, 68 K., Wen, 76 Q., Wessels, 103 J., Westerhoff, 43 U., Wiechula, 43 J., Wikne, 66 J., Wilk, 1 A., Wilk, 43 G., Williams, 89 M. C. S., Willis, 26 N., Windelband, 56 B., 66 C., Xu, Yang, 68 C., Yang, 68 H., Yasnopolskiy, 66 S., Yermia, 16 F., 27 J., Yi, Yin, 73 Z., Yokoyama, 68 H., Yoo, 76 I. K., Yuan, 73 X., Yurevich, jj V., Yushmanov, 44 I., Zabrodin, 16 E., Zagreev, 1 B., Zalite, 15 A., Zampolli, 50 C., Zanevsky, kk Y. u., Zaporozhets, 44 S., Zarochentsev, 44 A., Za´vada, 30 P., Zbroszczyk, 109 H., Zelnicek, 106 P., Zenin, 2 A., Zepeda, 59 A., Zgura, 70 I., Zhalov, 83 M., Zhang, 50 X., Zhou, b. D., Zhou, 68 S., Zhu, 103 J., Zichichi, 68 A., Zinchenko, t. A., Zinovjev, 44 G., Zoccarato, 62 Y., Zycha´cˇek, 71 V., Zynovyev62, M., K., Aamodt, 1 N., Abel, 2 U., Abeysekara, 3 A., Abrahantes Quintana, 4 A., Abramyan, 5 D., Adamova´, 6 M. M., Aggarwal, 7 G., Aglieri Rinella, 8 A. G., Agoc, 9 S., Aguilar Salazar, 10 Z., Ahammed, 11 A., Ahmad, 12 N., Ahmad, 12 S. U., Ahn, b. R., Akimoto, 14 A., Akindinov, 15 D., Aleksandrov, 16 B., Alessandro, 17 R., Alfaro Molina, 10 A., Alici, 18 E., Almara´z Avin˜a, 10 J., Alme, 19 T., Alt, c. V., Altini, 20 S., Altinpinar, 21 C., Andrei, 22 A., Andronic, 21 G., Anelli, 8 V., Angelov, c. C., Anson, 23 T., Anticˇic´, 24 F., Antinori, d. S., Antinori, 18 K., Antipin, 25 D., Anton´czyk, 25 P., Antonioli, 26 A., Anzo, 10 L., Aphecetche, 27 H., Appelsha¨user, 25 S., Arcelli, 18 R., Arceo, 10 A., Arend, 25 N., Armesto, 28 R., Arnaldi, 17 T., Aronsson, 29 I. C., Arsene, e. A., Asryan, 30 A., Augustinu, 8 R., Averbeck, 21 T. C., Awe, 31 J., A¨ ysto¨, 32 M. D., Azmi, 12 S., Bablok, 19 M., Bach, 33 A., Badala`, 34 Y. W., Baek, b. S., Bagnasco, 17 R., Bailhache, f. R., Bala, 35 A., Baldisseri, 36 A., Baldit, 37 J., Ba´n, 38 R., Barbera, 39 G. G., Barnafo¨ldi, 9 L. S., Barnby, 40 V., Barret, 37 J., Bartke, 41 F., Barile, 20 M., Basile, 18 V., Basmanov, 42 N., Bastid, 37 B., Bathen, 43 G., Batigne, 27 B., Batyunya, 44 C., Baumann, f. I. G., Bearden, 45 B., Becker, g. I., Belikov, 47 R., Bellwied, 48 E., Belmont Moreno, 10 A., Belogianni, 49 L., Benhabib, 27 S., Beole, 35 I., Berceanu, 22 A., Bercuci, h. E., Berdermann, 21 Y., Berdnikov, 50 L., Betev, 8 A., Bhasin, 51 A. K., Bhati, 7 L., Bianchi, 35 N., Bianchi, 52 C., Bianchin, 53 J., Bielcˇı´k, 54 J., Bielcˇı´kova´, 6 A., Bilandzic, 55 L., Bimbot, 56 E., Biolcati, 35 A., Blanc, 37 F., Blanco, i. F., Blanco, 57 D., Blau, 16 C., Blume, 25 M., Boccioli, 8 N., Bock, 23 A., Bogdanov, 58 H., Bøggild, 45 M., Bogolyubsky, 59 J., Bohm, 60 L., Boldizsa´r, 9 M., Bombara, 61 C., Bombonati, j. M., Bondila, 32 H., Borel, 36 A., Borisov, 62 C., Bortolin, k. S., Bose, Bosisio, Luciano, 64 F., Bossu´, 35 M., Botje, 55 S., Bo¨ttger, 2 G., Bourdaud, 27 B., Boyer, 56 M., Braun, 30 P., Braun Munzinger, 21, 65, c. L., Bravina, Bregant, Marco, l. T., Breitner, 2 G., Bruckner, 8 R., Brun, 8 E., Bruna, 29 G. E., Bruno, 20 D., Budnikov, 42 H., Buesching, 25 P., Buncic, 8 O., Busch, 66 Z., Buthelezi, 67 D., Caffarri, 53 X., Cai, 68 H., Caine, 29 E., Calvo, 69 E., Camacho, Camerini, Paolo, 64 M., Campbell, 8 V., Canoa Roman, 8 G. P., Capitani, 52 G., Cara Romeo, 26 F., Carena, Carena, 8. W., 8 F., Carminati, 8 A., Casanova Dı´az, 52 M., Caselle, 8 J., Castillo Castellano, 36 J. F., Castillo Hernandez, 21 V., Catanescu, Cattaruzza, Enrico, 64 C., Cavicchioli, 8 P., Cerello, 17 V., Chambert, 56 B., Chang, 60 S., Chapeland, 8 A., Charpy, 56 J. L., Charvet, 36 S., Chattopadhyay, 63 S., Chattopadhyay, 11 M., Cherney, 3 C., Cheshkov, 8 B., Cheyni, 71 E., Chiavassa, 35 V., Chibante Barroso, 8 D. D., Chinellato, 72 P., Chochula, 8 K., Choi, 73 M., Chojnacki, 74 P., Christakoglou, 74 C. H., Christensen, 45 P., Christiansen, 75 T., Chujo, 76 F., Chuman, 77 C., Cicalo, 46 L., Cifarelli, 18 F., Cindolo, 26 J., Cleyman, 67 O., Cobanoglu, 35 J. P., Coffin, 47 S., Coli, 17 A., Colla, 8 G., Conesa Balbastre, 52 Z., Conesa del Valle, m. E. S., Conner, 78 P., Constantin, Contin, Giacomo, j. J. G., Contrera, 70 Y., Corrales Morale, 35 T. M., Cormier, 48 P., Cortese, 79 I., Corte´s Maldonado, 80 M. R., Cosentino, 72 F., Costa, 8 M. E., Cotallo, 57 E., Crescio, 70 P., Crochet, 37 E., Cuautle, 81 L., Cunqueiro, 52 J., Cussonneau, 27 A., Dainese, 82 H. H., Dalsgaard, 45 A., Danu, 83 I., Da, 63 A., Dash, 84 S., Dash, 84 G. O. V., de Barro, 85 A., De Caro, 86 G., de Cataldo, 87 J., de Cuveland, c. A., De Falco, 88 M., De Gaspari, 66 J., de Groot, 8 D., De Gruttola, 86 N., De Marco, 17 S., De Pasquale, 86 R., De Remigi, 17 R., de Rooij, 74 G., de Vaux, 67 H., Delagrange, 27 Y., Delgado, 69 G., Dellacasa, 79 A., Deloff, 89 V., Demanov, 42 E., De´ne, 9 A., Deppman, 85 G., D’Erasmo, 20 D., Derkach, 30 A., Devaux, 37 D., Di Bari, 20 C., Di Giglio, j. S., Di Liberto, 90 A., Di Mauro, 8 P., Di Nezza, 52 M., Dialina, 27 L., Dı´az, 81 R., Dı´az, 32 T., Dietel, 43 R., Divia`, 8 Ø., Djuvsland, 19 V., Dobretsov, 16 A., Dobrin, 75 T., Dobrowolski, 89 B., Do¨nigu, 21 I., Domı´nguez, 81 D. M. M., Don, 91 O., Dordic, 1 A. K., Dubey, 11 J., Dubuisson, 8 L., Ducroux, 71 P., Dupieux, 37 A. K., Dutta Majumdar, 63 M. R., Dutta Majumdar, 11 D., Elia, 87 D., Emschermann, n. A., Enokizono, 31 B., Espagnon, 56 M., Estienne, 27 S., Esumi, 76 D., Evan, 40 S., Evrard, 8 G., Eyyubova, 1 C. W., Fabjan, o. D., Fabri, 82 J., Faivre, 92 D., Falchieri, 18 A., Fantoni, 52 M., Fasel, 21 O., Fateev, 44 R., Fearick, 67 A., Fedunov, 44 D., Fehlker, 19 V., Fekete, 93 D., Felea, 83 B., Fenton Olsen, p. G., Feofilov, 30 A., Ferna´ndez Te´llez, 80 E. G., Ferreiro, 28 A., Ferretti, 35 R., Ferretti, q. M. A. S., Figueredo, 85 S., Filchagin, 42 R., Fini, 87 F. M., Fionda, 20 E. M., Fiore, 20 M., Flori, j. Z., Fodor, 9 S., Foertsch, 67 P., Foka, 21 S., Fokin, 16 F., Formenti, 8 E., Fragiacomo, 94 M., Fragkiadaki, 49 U., Frankenfeld, 21 A., Frolov, 95 U., Fuch, 8 F., Furano, 8 C., Furget, 92 M., Fusco Girard, 86 J. J., Gaardhøje, 45 S., Gadrat, 92 M., Gagliardi, 35 A., Gago, 69 M., Gallio, 35 P., Ganoti, 49 M. S., Ganti, 11 C., Garabato, 21 C., Garcı´a Trapaga, 35 J., Gebelein, 2 R., Gemme, 79 M., Germain, 27 A., Gheata, 8 M., Gheata, 8 B., Ghidini, 20 P., Ghosh, 11 G., Giraudo, 17 P., Giubellino, 17 E., Gladysz Dziadu, 41 R., Glasow, a. P., Gla¨ssel, 66 A., Glenn, 96 R., Go´mez Jime´nez, 97 H., Gonza´lez Santo, 80 L. H., Gonza´lez Trueba, 10 P., Gonza´lez Zamora, 57 S., Gorbunov, c. Y., Gorbunov, 3 S., Gotovac, 98 H., Gottschlag, 43 V., Grabski, 10 R., Grajcarek, 66 A., Grelli, 74 A., Grigora, 8 C., Grigora, 8 V., Grigoriev, 58 A., Grigoryan, 5 S., Grigoryan, 44 B., Grinyov, 62 N., Grion, 94 P., Gro, 75 J. F., Grosse Oetringhau, 8 J. Y., Grossiord, Grosso, Raffaele, 82 F., Guber, 99 R., Guernane, 92 C., Guerra, 69 B., Guerzoni, 18 K., Gulbrandsen, 45 H., Gulkanyan, 5 T., Gunji, 14 A., Gupta, 51 R., Gupta, 51 H. A., Gustafsson, a. H., Gutbrod, 21 Ø., Haaland, 19 C., Hadjidaki, 56 M., Haiduc, 83 H., Hamagaki, 14 G., Hamar, 9 J., Hamblen, 100 B. H., Han, 101 J. W., Harri, 29 M., Hartig, 25 A., Harutyunyan, 5 D., Hasch, 52 D., Hasegan, 83 D., Hatzifotiadou, 26 A., Hayrapetyan, 5 M., Heide, 43 M., Heinz, 29 H., Helstrup, 102 A., Herghelegiu, 22 C., Herna´ndez, 21 G., Herrera Corral, 70 N., Herrmann, 66 K. F., Hetland, 102 B., Hick, 29 A., Hiei, 77 P. T., Hille, r. B., Hippolyte, 47 T., Horaguchi, s. Y., Hori, 14 P., Hristov, 8 I., Hrˇivna´cˇova´, 56 S., Hu, 103 M., Huang, 19 S., Huber, 21 T. J., Humanic, 23 D., Hutter, 33 D. S., Hwang, 101 R., Ichou, 27 R., Ilkaev, 42 I., Ilkiv, 89 M., Inaba, 76 P. G., Innocenti, 8 M., Ippolitov, 16 M., Irfan, 12 C., Ivan, 74 A., Ivanov, 30 M., Ivanov, 21 V., Ivanov, 50 T., Iwasaki, 77 A., Jachołkowski, 8 P., Jacob, 104 L., Jancˇurova´, 44 S., Jangal, 47 R., Janik, 93 C., Jena, 84 S., Jena, 105 L., Jirden, 8 G. T., Jone, 40 P. G., Jone, 40 P., Jovanovic´, 40 H., Jung, 13 W., Jung, 13 A., Jusko, 40 A. B., Kaidalov, 15 S., Kalcher, c. P., Kalinˇa´k, 38 M., Kalisky, 43 T., Kalliokoski, 32 A., Kalweit, 65 A., Kamal, 12 R., Kamerman, 74 K., Kanaki, 19 E., Kang, 13 J. H., Kang, 60 J., Kapitan, 6 V., Kaplin, 58 S., Kapusta, 8 O., Karavichev, 99 T., Karavicheva, 99 E., Karpechev, 99 A., Kazantsev, 16 U., Kebschull, 2 R., Keidel, 78 M. M., Khan, 12 S. A., Khan, 11 A., Khanzadeev, 50 Y., Kharlov, 59 D., Kikola, 106 B., Kileng, 102 D. J., Kim, 32 D. S., Kim, 13 D. W., Kim, 13 H. N., Kim, 13 J., Kim, 59 J. H., Kim, 101 J. S., Kim, 13 M., Kim, 60 S. H., Kim, 13 S., Kim, 101 Y., Kim, 60 S., Kirsch, 8 I., Kisel, e. S., Kiselev, 15 A., Kisiel, j. J. L., Klay, 107 J., Klein, 66 C., Klein Bo¨sing, n. M., Kliemant, 25 A., Klovning, 19 A., Kluge, 8 M. L., Knichel, 21 S., Kniege, 25 K., Koch, 66 R., Kolevatov, 1 A., Kolojvari, 30 V., Kondratiev, 30 N., Kondratyeva, 58 A., Konevskih, 99 E., Kornas´, 41 R., Kour, 40 M., Kowalski, 41 S., Kox, 92 K., Kozlov, 16 J., Kral, l. I., Kra´lik, 38 F., Kramer, 25 I., Krau, e. A., Kravcˇa´kova´, 61 T., Krawutschke, 108 M., Krivda, 40 D., Krumbhorn, 66 M., Kru, 54 E., Kryshen, 50 M., Krzewicki, 55 Y., Kucheriaev, 16 C., Kuhn, 47 P. G., Kuijer, 55 L., Kumar, 7 N., Kumar, 7 R., Kupczak, 106 P., Kurashvili, 89 A., Kurepin, 99 A. N., Kurepin, 99 A., Kuryakin, 42 S., Kushpil, 6 V., Kushpil, 6 M., Kutouski, 44 H., Kvaerno, 1 M. J., Kweon, 66 Y., Kwon, 60 P., La Rocca, t. F., Lackner, 8 P., Ladro´n de Guevara, 57 V., Lafage, 56 C., Lal, 51 C., Lara, 2 D. T., Larsen, 19 G., Laurenti, 26 C., Lazzeroni, 40 Y., Le Bornec, 56 N., Le Bri, 27 H., Lee, 73 K. S., Lee, 13 S. C., Lee, 13 F., Lefe`vre, 27 M., Lenhardt, 27 L., Leistam, 8 J., Lehnert, 25 V., Lenti, 87 H., Leo´n, 10 I., Leo´n Monzo´n, 97 H., Leo´n Varga, 25 P., Le´vai, 9 X., Li, 103 Y., Li, 103 R., Lietava, 40 S., Lindal, 1 V., Lindenstruth, c. C., Lippmann, 8 M. A., Lisa, 23 L., Liu, 19 V., Loginov, 58 S., Lohn, 8 X., Lopez, 37 M., Lo´pez Noriega, 56 R., Lo´pez Ramı´rez, 80 E., Lo´pez Torre, 4 G., Løvhøiden, 1 A., Lozea Feijo Soare, 85 S., Lu, 103 M., Lunardon, 53 G., Luparello, 35 L., Luquin, 27 J. R., Lutz, 47 K., Ma, 68 R., Ma, 29 D. M., Madagodahettige Don, 91 A., Maevskaya, 99 M., Mager, j. D. P., Mahapatra, 84 A., Maire, 47 I., Makhlyueva, 8 D., Mal’Kevich, 15 M., Malaev, 50 K. J., Malagalage, 3 I., Maldonado Cervante, 81 M., Malek, 56 L., Malinina, u. T., Malkiewicz, 32 P., Malzacher, 21 A., Mamonov, 42 L., Manceau, 37 L., Mangotra, 51 V., Manko, 16 F., Manso, 37 V., Manzari, 87 Y., Mao, v. J., Maresˇ, Margagliotti, Giacomo, 64 A., Margotti, 26 A., Marı´n, 21 I., Martashvili, 100 P., Martinengo, 8 M. I., Martı´nez Herna´ndez, 80 A., Martı´nez Davalo, 10 G., Martı´nez Garcı´a, 27 Y., Maruyama, 77 A., Marzari Chiesa, 35 S., Masciocchi, 21 M., Masera, 35 M., Masetti, 18 A., Masoni, 46 L., Massacrier, 71 M., Mastromarco, 87 A., Mastroserio, j. Z. L., Matthew, 40 A., Matyja, w. D., Mayani, 81 G., Mazza, 17 M. A., Mazzoni, 90 F., Meddi, 110 A., Menchaca Rocha, 10 P., Mendez Lorenzo, 8 M., Meoni, 8 J., Mercado Pe´rez, 66 P., Mereu, 17 Y., Miake, 76 A., Michalon, 47 N., Miftakhov, 50 L., Milano, 35 J., Milosevic, 1 F., Minafra, 20 A., Mischke, 74 D., Mis´kowiec, 21 C., Mitu, 83 K., Mizoguchi, 77 J., Mlynarz, 48 B., Mohanty, 11 L., Molnar, j. M. M., Mondal, 11 L., Montan˜o Zetina, x. M., Monteno, 17 E., Monte, 57 M., Morando, 53 S., Moretto, 53 A., Morsch, 8 T., Moukhanova, 16 V., Muccifora, 52 E., Mudnic, 98 S., Muhuri, 11 H., Mu¨ ller, 8 M. G., Munhoz, 85 J., Munoz, 80 L., Musa, 8 A., Musso, 17 B. K., Nandi, 105 R., Nania, 26 E., Nappi, 87 F., Navach, 20 S., Navin, 40 T. K., Nayak, 11 S., Nazarenko, 42 G., Nazarov, 42 A., Nedosekin, 15 F., Nendaz, 71 J., Newby, 96 A., Nianine, 16 M., Nicassio, j. B. S., Nielsen, 45 S., Nikolaev, 16 V., Nikolic, 24 S., Nikulin, 16 V., Nikulin, 50 B. S., Nilsen, 3 M. S., Nilsson, 1 F., Noferini, 26 P., Nomokonov, 44 G., Nooren, 74 N., Novitzky, 32 A., Nyatha, 105 C., Nygaard, 45 A., Nyiri, 1 J., Nystrand, 19 A., Ochirov, 30 G., Odyniec, 104 H., Oeschler, 65 M., Oinonen, 32 K., Okada, 14 Y., Okada, 77 M., Oldenburg, 8 J., Oleniacz, 106 C., Oppedisano, 17 F., Orsini, 36 A., Ortiz Velasquez, 81 G., Ortona, 35 A., Oskarsson, 75 F., Osmic, 8 L., O¨ sterman, 75 P., Ostrowski, 106 I., Otterlund, 75 J., Otwinowski, 21 G., Øvrebekk, 19 K., Oyama, 66 K., Ozawa, 14 Y., Pachmayer, 66 M., Pachr, 54 F., Padilla, 35 P., Pagano, 86 G., Paic´, 81 F., Painke, 2 C., Pajare, 28 S., Pal, y. S. K., Pal, 11 A., Palaha, 40 A., Palmeri, 34 R., Panse, 2 V., Papikyan, 5 G. S., Pappalardo, 34 W. J., Park, 21 B., Pastircˇa´k, 38 C., Pastore, 87 V., Paticchio, 87 A., Pavlinov, 48 T., Pawlak, 106 T., Peitzmann, 74 A., Pepato, 82 H., Pereira, 36 D., Peressounko, 16 C., Pe´rez, 69 D., Perini, 8 D., Perrino, j. W., Peryt, 106 J., Peschek, c. A., Pesci, 26 V., Peskov, j. Y., Pestov, 95 A. J., Peter, 8 V., Petra´cˇek, 54 A., Petridi, a. M., Petri, 22 P., Petrov, 40 M., Petrovici, 22 C., Petta, 39 J., Peyre´, Piano, Stefano, 94 A., Piccotti, 17 M., Pikna, 93 P., Pillot, 27 O., Pinazza, j. L., Pinsky, 91 N., Pitz, 25 F., Piuz, 8 R., Platt, 40 M., Płoskon´, 104 J., Pluta, 106 T., Pocheptsov, z. S., Pochybova, 9 P. L. M., Podesta Lerma, 97 F., Poggio, 35 M. G., Poghosyan, 35 K., Pola´k, 109 B., Polichtchouk, 59 P., Polozov, 15 V., Polyakov, 50 B., Pommeresch, 19 A., Pop, 22 F., Posa, 20 V., Pospı´sˇil, 54 B., Potukuchi, 51 J., Poutha, 56 S. K., Prasad, 11 R., Preghenella, t. F., Prino, 17 C. A., Pruneau, 48 I., Pshenichnov, 99 G., Puddu, 88 P., Pujahari, 105 A., Pulvirenti, 39 A., Punin, 42 V., Punin, 42 M., Putisˇ, 61 J., Putschke, 29 E., Quercigh, 8 A., Rachevski, 94 A., Rademaker, 8 S., Radomski, 66 T. S., Ra¨iha¨, 32 J., Rak, 32 A., Rakotozafindrabe, 36 L., Ramello, 79 A., Ramı´rez Reye, 70 M., Rammler, 43 R., Raniwala, 111 S., Raniwala, 111 S. S., Ra¨sa¨nen, 32 I., Rashevskaya, 94 S., Rath, 84 K. F., Read, 100 J. S., Real, 92 K., Redlich, aa R., Renfordt, 25 A. R., Reolon, 52 A., Reshetin, 99 F., Rettig, c. J. P., Revol, 8 K., Reyger, bb H., Ricaud, 65 L., Riccati, 17 R. A., Ricci, 112 M., Richter, 19 P., Riedler, Riegler, 8. W., 8 F., Riggi, 39 A., Rivetti, 17 M., Rodriguez Cahuantzi, 80 K., Røed, 102 D., Ro¨hrich, cc S., Roma´n Lo´pez, 80 R., Romita, e. F., Ronchetti, 52 P., Rosinsky´, 8 P., Rosnet, 37 S., Rossegger, 8 A., Rossi, dd F., Roukoutaki, ee S., Rousseau, 56 C., Roy, m. P., Roy, 63 A. J., Rubio Montero, Rui, Rinaldo, 64 I., Rusanov, 66 G., Russo, 86 E., Ryabinkin, 16 A., Rybicki, 41 S., Sadovsky, 59 K. S. ˇ., Afarˇı´k, 8 R., Sahoo, 53 J., Saini, 11 P., Saiz, 8 D., Sakata, 76 C. A., Salgado, 28 R., Salgueiro Domingues da Silva, 8 S., Salur, 104 T., Samanta, 11 S., Sambyal, 51 V., Samsonov, 50 L. S. ˇ., A´ndor, 38 A., Sandoval, 10 M., Sano, 76 S., Sano, 14 R., Santo, 43 R., Santoro, 20 J., Sarkamo, 32 P., Saturnini, 37 E., Scapparone, 26 F., Scarlassara, 53 R. P., Scharenberg, 113 C., Schiaua, 22 R., Schicker, 66 H., Schindler, 8 C., Schmidt, 21 H. R., Schmidt, 21 K., Schossmaier, 8 S., Schreiner, 8 S., Schuchmann, 25 J., Schukraft, 8 Y., Schutz, 27 K., Schwarz, 21 K., Schweda, 66 G., Scioli, 18 E., Scomparin, 17 P. A., Scott, 40 G., Segato, 53 D., Semenov, 30 S., Senyukov, 79 J., Seo, 13 S., Serci, 88 L., Serkin, 81 E., Serradilla, 57 A., Sevcenco, 83 I., Sgura, 20 G., Shabratova, 44 R., Shahoyan, 8 G., Sharkov, 15 N., Sharma, 7 S., Sharma, 51 K., Shigaki, 77 M., Shimomura, 76 K., Shtejer, 4 Y., Sibiriak, 16 M., Siciliano, 35 E., Sicking, ff E., Siddi, 46 T., Siemiarczuk, 89 A., Silenzi, 18 D., Silvermyr, 31 E., Simili, 74 G., Simonetti, j. R., Singaraju, 11 R., Singh, 51 V., Singhal, 11 B. C., Sinha, 11 T., Sinha, 63 B., Sitar, 93 M., Sitta, 79 T. B., Skaali, 1 K., Skjerdal, 19 R., Smakal, 54 N., Smirnov, 29 R., Snelling, 55 H., Snow, 40 C., Søgaard, 45 A., Soloviev, 59 H. K., Soltveit, 66 R., Soltz, 96 W., Sommer, 25 C. W., Son, 73 H., Son, 101 M., Song, 60 C., Soo, 8 F., Soramel, 53 D., Soyk, 21 M., Spyropoulou Stassinaki, 49 B. K., Srivastava, 113 J., Stachel, 66 F., Staley, 36 E., Stan, 83 G., Stefanek, 89 G., Stefanini, 8 T., Steinbeck, c. E., Stenlund, 75 G., Steyn, 67 D., Stocco, w. R., Stock, 25 P., Stolpovsky, 59 P., Strmen, 93 A. A. P., Suaide, 85 M. A., Subieta Va´squez, 35 T., Sugitate, 77 C., Suire, 56 M. S. ˇ., Umbera, 6 T., Susa, 24 D., Swoboda, 8 J., Symon, 104 A., Szanto de Toledo, 85 I., Szarka, 93 A., Szostak, 46 M., Szuba, 106 M., Tadel, 8 C., Tagridi, 49 A., Takahara, 14 J., Takahashi, 72 R., Tanabe, 76 J. D., Tapia Takaki, 56 H., Taureg, 8 A., Tauro, 8 M., Tavlet, 8 G., Tejeda Mun˜oz, 80 A., Telesca, 8 C., Terrevoli, 20 J., Tha¨der, c. R., Tieulent, 71 D., Tlusty, 54 A., Toia, 8 T., Tolyhy, 9 C., Torcato de Mato, 8 H., Torii, 77 G., Torralba, 2 L., Toscano, 17 F., Tosello, 17 A., Tournaire, gg T., Traczyk, 106 P., Tribedy, 11 G., Tro¨ger, 2 D., Truesdale, 23 W. H., Trzaska, 32 G., Tsiledaki, 66 E., Tsili, 49 T., Tsuji, 14 A., Tumkin, 42 R., Turrisi, 82 A., Turvey, 3 T. S., Tveter, 1 H., Tydesjo¨, 8 K., Tywoniuk, 1 J., Ulery, 25 K., Ullaland, 19 A., Ura, 88 J., Urba´n, 61 G. M., Urciuoli, 90 G. L., Usai, 88 A., Vacchi, 94 M., Vala, hh L., Valencia Palomo, 10 S., Vallero, 66 N., van der Kolk, 55 P., Vande Vyvre, 8 M., van Leeuwen, 74 L., Vannucci, 112 A., Varga, 80 R., Varma, 105 A., Vasiliev, 16 I., Vassiliev, ee M., Vasileiou, 49 V., Vechernin, Venaruzzo, Massimo, 64 E., Vercellin, 35 S., Vergara, 80 R., Vernet, ii M., Verweij, 74 I., Vetlitskiy, 15 L., Vickovic, 98 G., Viesti, 53 O., Vikhlyantsev, 42 Z., Vilakazi, 67 O., Villalobos Baillie, 40 A., Vinogradov, 16 L., Vinogradov, 30 Y., Vinogradov, 42 T., Virgili, 86 Y. P., Viyogi, 11 A., Vodopianov, 44 K., Voloshin, 15 S., Voloshin, 48 G., Volpe, 20 B., von Haller, 8 D., Vranic, 21 J., Vrla´kova´, 61 B., Vulpescu, 37 B., Wagner, 19 V., Wagner, 54 L., Wallet, 8 R., Wan, m. D., Wang, 68 Y., Wang, 66 Y., Wang, 68 K., Watanabe, 76 Q., Wen, 103 J., Wessel, 43 U., Westerhoff, 43 J., Wiechula, 66 J., Wikne, 1 A., Wilk, 43 G., Wilk, 89 M. C. S., William, 26 N., Willi, 56 B., Windelband, 66 C., Xu, 68 C., Yang, 68 H., Yang, 66 S., Yasnopolskiy, 16 F., Yermia, 27 J., Yi, 73 Z., Yin, 68 H., Yokoyama, 76 I. K., Yoo, 73 X., Yuan, jj V., Yurevich, 44 I., Yushmanov, 16 E., Zabrodin, 1 B., Zagreev, 15 A., Zalite, 50 C., Zampolli, Zanevsky, kk Y. u., 44 S., Zaporozhet, 44 A., Zarochentsev, 30 P., Za´vada, 109 H., Zbroszczyk, 106 P., Zelnicek, 2 A., Zenin, 59 A., Zepeda, 70 I., Zgura, 83 M., Zhalov, 50 X., Zhang, b. D., Zhou, 68 S., Zhou, 103 J., Zhu, 68 A., Zichichi, t. A., Zinchenko, 44 G., Zinovjev, 62 Y., Zoccarato, 71 V., Zycha´cˇek, and M., Zynovyev62
- Subjects
ALICE ,LHC ,Bose-Einstein - Abstract
We report on the measurement of two-pion correlation functions from pp collisions at s= 900 GeV performed by the ALICE experiment at the Large Hadron Collider. Our analysis shows an increase of the Hanbury Brown–Twiss radius with increasing event multiplicity, in line with other measurements done in particle- and nuclear collisions. Conversely, the strong decrease of the radius with increasing transverse momentum, as observed at the Relativistic Heavy Ion Collider and at Tevatron, is not manifest in our data.
- Published
- 2010
7. Pancreatic Cancer
- Author
-
Ralph R. Dobelbower, Steven M. Wagner, Ronald J. Fadell, John M. Howard, and Liberto J. A. DiDio
- Published
- 1990
- Full Text
- View/download PDF
8. Perturbations of the T-cell immune repertoire in kidney transplant rejection
- Author
-
Sigdel, TK, primary, Fields, PA, additional, Liberto, J, additional, Damm, I, additional, Kerwin, M, additional, Robins, HS, additional, and Sarwal, MM, additional
- Full Text
- View/download PDF
9. Competency Evaluations in a VA Hospital: A 10-Year Perspective
- Author
-
Knowles, F. E., Liberto, J., Baker, F. M., and Ruskin, P. E.
- Published
- 1994
- Full Text
- View/download PDF
10. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.
- Author
-
Rothman, R B, Gorelick, D A, Heishman, S J, Eichmiller, P R, Hill, B H, Norbeck, J, and Liberto, J G
- Abstract
Several lines of evidence, including the well-established observation that kappa opiate agonists produce dysphoria and psychotomimetic effects in humans, suggest that dysfunction of the endogenous kappa opioid system may contribute to opioid and cocaine addiction. The objective of this open-label study was to determine the effectiveness of a functional kappa antagonist as a treatment for opioid dependence. This was accomplished by combining a partial mu agonist/kappa antagonist (buprenorphine, 4 mg, sublingual) with a mu antagonist (naltrexone, 50 mg by mouth), theoretically leaving kappa antagonism as the major medication effect. Subjects were treatment-seeking heroin-dependent (as per Diagnostic and Statistical Manual of Mental Disorders, 4th ed.) men (41 +/- 7 years old; 19 +/- 8 years heroin use) eligible for methadone maintenance. After inpatient detoxification and a naloxone-challenge test to verify that they were not physically dependent on opioids, subjects received naltrexone. Starting on the fourth day, patients also received liquid buprenorphine. All patients received medication at the clinic 6 days per week and a full program of psychosocial treatment. The major endpoints of the study were: pupil diameter to determine if the mu agonist effects of buprenorphine were blocked by naltrexone, urine toxicology, and retention in treatment. Five patients (33%) completed the 3-month study. Four were abstinent from opioids and cocaine for the entire study, and one was abstinent from opioids and cocaine for the last 9 weeks. Six subjects dropped out due to either minor side effects or disliking the sensation of sublingual buprenorphine. There were no significant changes in pupillary diameter. The positive response to treatment exceeds that expected from naltrexone alone (90% dropout). These promising results suggest that controlled studies of this medication combination should be conducted. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
11. Internal Medicine Resident Addiction Training at the Veteran's Health Administration: A Qualitative Evaluation of Site Directors' Response to the 2022 ACGME Requirements.
- Author
-
Richardson C, Daniels K, Confer A, Saxon AJ, Gordon AJ, Liberto J, Albanese AP, Renner J, Edens E, and Kennedy AJ
- Subjects
- Humans, United States, Substance-Related Disorders therapy, Qualitative Research, Focus Groups, Accreditation, Male, Female, Internal Medicine education, United States Department of Veterans Affairs, Internship and Residency standards, Education, Medical, Graduate, Addiction Medicine education
- Abstract
Background: Substance use disorders (SUDs) are prevalent in the USA yet remain dramatically undertreated. To address this care gap, the Accreditation Council for Graduate Medical Education (ACGME) approved revisions to the Program Requirements for Graduate Medical Education (GME) in Internal Medicine, effective July 1, 2022, requiring addiction medicine training for all internal medicine (IM) residents. The Veterans Health Administration (VHA) is a clinical training site for many academic institutions that sponsor IM residencies. This focus group project evaluated VHA IM residency site directors' perspectives about providing addiction medical education within VHA IM training sites., Objective: To better understand the current state, barriers to, and facilitators of IM resident addiction medicine training at VHA sites., Design: This was a qualitative evaluation based on semi-structured video-based focus groups., Participants: Participants were VHA IM site directors based at a VHA hospital or clinic throughout the USA., Approach: Focus groups were conducted using a semi-structured group interview guide. Two investigators coded each focus group independently, then met to create a final adjudicated coding scheme. Thematic analysis was used to identify key themes., Key Results: Forty-three participants from 38 VHA sites participated in four focus groups (average size: 11 participants). Six themes were identified within four pre-defined categories. Current state of training: most VHA sites offered no formal training in addiction medicine for IM residents. Barriers: addiction experts are often located outside of IM settings, and ACGME requirements were non-specific. Facilitators: clinical champions help support addiction training. Desired next steps: participants desired incentives to train or hire local champions and a pre-packaged didactic curriculum., Conclusions: Developing competent clinical champions and leveraging VHA addiction specialists from non-IM settings would create more addiction training opportunities for IM trainees at VHA sites. These insights can likely be applied to IM training at non-VHA sites., (© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.)
- Published
- 2024
- Full Text
- View/download PDF
12. History and current status of contingency management programs in the Department of Veterans Affairs.
- Author
-
DePhilippis D, Khazanov G, Christofferson DE, Wesley CW, Burden JL, Liberto J, and McKay JR
- Subjects
- Humans, United States, Behavior Therapy, Delivery of Health Care, Substance-Related Disorders therapy, Veterans, Alcoholism
- Abstract
Objective: This article describes the Department of Veterans Affairs (VA) national implementation of contingency management within VA substance use disorder (SUD) treatment programs., Methods: The rationale for implementing CM, role of VA leadership, and training and supervision procedures are detailed. The role of the Veterans Canteen Service (VCS) in sustaining the CM implementation through the donation of incentives is outlined. Updated outcomes from the primary program, CM to incentivize stimulant abstinence, are provided. Data presented were gathered from June 2011 to January 2023, from VA facilities across the country., Results: More than 6000 Veterans from 119 VA facilities have received CM in a 12-week program in which two urine samples are obtained per week, with 92% of the samples negative for the targeted substance. Two other CM pilot projects are described. The first incentivizes adherence to injectable medications for opioid and alcohol use disorders, with over 580 veterans from 27 VA sites participating to date. The second incentivized smoking cessation in 312 patients from four sites. A new initiative in which CM is implemented in smaller community-based VA facilities through use of onsite prize cabinets is presented and the possibility of providing CM remotely in VA is discussed., Conclusions: It has proved feasible to implement abstinence CM and several other CM pilot programs at many VA facilities. Factors that contributed to the success of the VA CM rollout, challenges that were encountered along the way, and lessons learned that may facilitate wider use of CM outside VA are discussed., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. The authors are all employed by the Department of Veterans Affairs., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF
13. Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice.
- Author
-
Vistein R, Winer B, Myers S, Liberto J, Ishiyama S, Guo X, Saeki H, Wang TL, Shih IM, and Gabrielson K
- Subjects
- Animals, Female, Mice, Disease Models, Animal, DNA-Binding Proteins, Heterografts, PAX8 Transcription Factor, PTEN Phosphohydrolase, Transcription Factors, Ultrasonography, Gene Deletion, Endometrial Neoplasms diagnostic imaging, Endometrial Neoplasms genetics
- Abstract
Uterine cancers can be studied in mice due to the ease of handling and genetic manipulation in these models. However, these studies are often limited to assessing pathology post-mortem in animals euthanized at multiple time points in different cohorts, which increases the number of mice needed for a study. Imaging mice in longitudinal studies can track the progression of disease in individual animals, reducing the number of mice needed. Advances in ultrasound technology have allowed for the detection of micrometer-level changes in tissues. Ultrasound has been used to study follicle maturation in ovaries and xenograft growth but has not been applied to morphological changes in the mouse uterus. This protocol examines the juxtaposition of pathology with in vivo imaging comparisons in an induced endometrial cancer mouse model. The features observed by ultrasound were consistent with the degree of change seen by gross pathology and histology. Ultrasound was found to be highly predictive of the observed pathology, supporting the incorporation of ultrasonography into longitudinal studies of uterine diseases such as cancer in mice.
- Published
- 2023
- Full Text
- View/download PDF
14. Perturbations of the T-cell immune repertoire in kidney transplant rejection.
- Author
-
Sigdel TK, Fields PA, Liberto J, Damm I, Kerwin M, Hood J, Towfighi P, Sirota M, Robins HS, and Sarwal MM
- Subjects
- Humans, Cross-Sectional Studies, Postoperative Complications, Biopsy, Antibodies, T-Lymphocytes, Kidney Transplantation adverse effects
- Abstract
In this cross-sectional and longitudinal analysis of mapping the T-cell repertoire in kidney transplant recipients, we have investigated and validated T-cell clonality, immune repertoire chronology at rejection, and contemporaneous allograft biopsy quantitative tissue injury, to better understand the pathobiology of acute T-cell fraction, T-cell repertoire and antibody-mediated kidney transplant rejection. To follow the dynamic evolution of T-cell repertoire changes before and after engraftment and during biopsy-confirmed acute rejection, we sequenced 323 peripheral blood samples from 200 unique kidney transplant recipients, with (n=100) and without (n=100) biopsy-confirmed acute rejection. We report that patients who develop acute allograft rejection, have lower (p=0.01) T-cell fraction even before transplantation, followed by its rise after transplantation and at the time of acute rejection accompanied by high TCR repertoire turnover (p=0.004). Acute rejection episodes occurring after the first 6 months post-transplantation, and those with a component of antibody-mediated rejection, had the highest turnover; p=0.0016) of their T-cell repertoire. In conclusion, we validated that detecting repertoire changes in kidney transplantation correlates with post-transplant rejection episodes suggesting that T-cell receptor sequencing may provide recipient pre-transplant and post-transplant predictors of rejection risk., Competing Interests: Authors PF, JH, and HR were employed by Adaptive Biotechnologies. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Sigdel, Fields, Liberto, Damm, Kerwin, Hood, Towfighi, Sirota, Robins and Sarwal.)
- Published
- 2022
- Full Text
- View/download PDF
15. The Management of Substance Use Disorders: Synopsis of the 2021 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.
- Author
-
Perry C, Liberto J, Milliken C, Burden J, Hagedorn H, Atkinson T, McKay JR, Mooney L, Sall J, Sasson C, Saxon A, Spevak C, and Gordon AJ
- Subjects
- Humans, United States, United States Department of Veterans Affairs, Practice Guidelines as Topic, Substance-Related Disorders therapy, Veterans
- Abstract
Description: In August 2021, leadership within the U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) approved a joint clinical practice guideline (CPG) for the management of substance use disorders (SUDs). This synopsis summarizes key recommendations., Methods: In March 2020, the VA/DoD Evidence-Based Practice Work Group assembled a team to update the 2015 VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders that included clinical stakeholders and conformed to the National Academy of Medicine's tenets for trustworthy CPGs. The guideline panel developed key questions, systematically searched and evaluated the literature, created two 1-page algorithms, and distilled 35 recommendations for care using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. This synopsis presents the recommendations that were believed to be the most clinically impactful., Recommendations: The scope of the CPG is broad; however, this synopsis focuses on key recommendations for the management of alcohol use disorder, use of buprenorphine in opioid use disorder, contingency management, and use of technology and telehealth to manage patients remotely.
- Published
- 2022
- Full Text
- View/download PDF
16. Are x-waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x-waiver trainings.
- Author
-
Gordon AJ, Kenny M, Dungan M, Gustavson AM, Kelley AT, Jones AL, Hawkins E, Frank JW, Danner A, Liberto J, and Hagedorn H
- Subjects
- Cross-Sectional Studies, Humans, Opiate Substitution Treatment, United States, Buprenorphine therapeutic use, Opioid-Related Disorders drug therapy, Physicians
- Abstract
Background: In the United States, an x-waiver credential is necessary to prescribe buprenorphine medication treatment for opioid use disorder (B-MOUD). Historically, this process has required certified training, which could be a barrier to obtaining an x-waiver and subsequently prescribing. To address this barrier, the US recently removed the training requirement for some clinicians. We sought to determine if clinicians who attended x-waiver training went on to obtain an x-waiver and prescribe B-MOUD, and to examine what facilitated or impeded B-MOUD prescribing., Methods: In September 2020, we conducted a cross-sectional, electronic survey of attendees of 15 in-person x-waiver pieces of training from June 2018 to January 2020 within the Veterans Health Administration (VHA). Of the attendees (n = 321), we surveyed current VHA clinicians who recalled taking the training. The survey assessed whether clinicians obtained the x-waiver, had prescribed B-MOUD, and barriers or facilitators that influenced B-MOUD prescribing., Results: Of 251 eligible participants, 62 (24.7%) responded to the survey, including 27 (43.5%) physicians, 16 (25.8%) advanced practice clinicians, and 12 (19.4%) pharmacists. Of the 43 clinicians who could prescribe, 29 (67.4%) had obtained their x-waiver and 16 (37.2%) had reported prescribing B-MOUD. Prominent barriers to prescribing B-MOUD included a lack of supporting clinical staff and competing demands on time. The primary facilitator to prescribing was leadership support., Conclusion and Scientific Significance: Nine months after x-waiver training, two-thirds of clinicians with prescribing credentials had obtained their x-waiver and one-third were prescribing B-MOUD. Removing the x-waiver training may not have the intended policy effect as other barriers to B-MOUD prescribing persist., (Published 2022. This article is a U.S. Government work and is in the public domain in the USA.)
- Published
- 2022
- Full Text
- View/download PDF
17. Effects of Venoconstrictive Thigh Cuffs on Dry Immersion-Induced Ophthalmological Changes.
- Author
-
Kermorgant M, Sadegh A, Geeraerts T, Varenne F, Liberto J, Roubelat FP, Bataille N, Bareille MP, Beck A, Godard B, Golemis A, Nasr N, Arvanitis DN, Hélissen O, Senard JM, Pavy-Le Traon A, and Soler V
- Abstract
Neuro-ophthalmological changes named spaceflight associated neuro-ocular syndrome (SANS) reported after spaceflights are important medical issues. Dry immersion (DI), an analog to microgravity, rapidly induces a centralization of body fluids, immobilization, and hypokinesia similar to that observed during spaceflight. The main objectives of the present study were 2-fold: (1) to assess the neuro-ophthalmological impact during 5 days of DI and (2) to determine the effects of venoconstrictive thigh cuffs (VTC), used as a countermeasure to limit headward fluid shift, on DI-induced ophthalmological adaptations. Eighteen healthy male subjects underwent 5 days of DI with or without VTC countermeasures. The subjects were randomly assigned into two groups of 9: a control and cuffs group. Retinal and optic nerve thickness were assessed with spectral-domain optical coherence tomography (OCT). Optic nerve sheath diameter (ONSD) was measured by ocular ultrasonography and used to assess indirect changes in intracranial pressure (ICP). Intraocular pressure (IOP) was assessed by applanation tonometry. A higher thickness of the retinal nerve fiber layer (RNFL) in the temporal quadrant was observed after DI. ONSD increased significantly during DI and remained higher during the recovery phase. IOP did not significantly change during and after DI. VTC tended to limit the ONSD enlargement but not the higher thickness of an RNFL induced by DI. These findings suggest that 5 days of DI induced significant ophthalmological changes. VTC were found to dampen the ONSD enlargement induced by DI., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Kermorgant, Sadegh, Geeraerts, Varenne, Liberto, Roubelat, Bataille, Bareille, Beck, Godard, Golemis, Nasr, Arvanitis, Hélissen, Senard, Pavy-Le Traon and Soler.)
- Published
- 2021
- Full Text
- View/download PDF
18. Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells.
- Author
-
Osipov A, Blair AB, Liberto J, Wang J, Li K, Herbst B, Xu Y, Li S, Niu N, Rashid R, Ding D, Liu Y, Wang Z, Wolfgang CL, Burkhart RA, Laheru D, and Zheng L
- Subjects
- Animals, CD8-Positive T-Lymphocytes immunology, Carcinoma, Pancreatic Ductal immunology, Carcinoma, Pancreatic Ductal pathology, Cell Line, Tumor, Disease Models, Animal, Female, Humans, Mice, Mice, Inbred C57BL, Pancreatic Neoplasms immunology, Pancreatic Neoplasms pathology, Radiation-Sensitizing Agents, Tumor Microenvironment drug effects, CD8-Positive T-Lymphocytes drug effects, Carcinoma, Pancreatic Ductal radiotherapy, Focal Adhesion Protein-Tyrosine Kinases antagonists & inhibitors, Pancreatic Neoplasms radiotherapy, Protein Kinase Inhibitors pharmacology
- Abstract
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy, due in large part to its resistance to conventional therapies, including radiotherapy (RT). Despite RT exerting a modest antitumor response, it has also been shown to promote an immunosuppressive tumor microenvironment. Previous studies demonstrated that focal adhesion kinase inhibitors (FAKi) in clinical development inhibit the infiltration of suppressive myeloid cells and T regulatory (T regs) cells, and subsequently enhance effector T cell infiltration. FAK inhibitors in clinical development have not been investigated in combination with RT in preclinical murine models or clinical studies. Thus, we investigated the impact of FAK inhibition on RT, its potential as an RT sensitizer and immunomodulator in a murine model of PDAC., Methods: We used a syngeneic orthotopic murine model to study the effect of FAKi on hypofractionated RT., Results: In this study we showed that IN10018, a small molecular FAKi, enhanced antitumor response to RT. Antitumor activity of the combination of FAKi and RT is T cell dependent. FAKi in combination with RT enhanced CD8+ T cell infiltration significantly in comparison to the radiation or FAKi treatment alone ( P < 0.05). FAKi in combination with radiation inhibited the infiltration of granulocytes but enhanced the infiltration of macrophages and T regs in comparison with the radiation or FAKi treatment alone ( P < 0.01)., Conclusions: These results support the clinical development of FAKi as a radiosensitizer for PDAC and combining FAKi with RT to prime the tumor microenvironment of PDAC for immunotherapy., Competing Interests: Conflict of interest statement Lei Zheng receives grant support from Bristol-Meyer Squibb, Merck, iTeos, Amgen, NovaRock, Inxmed, and Halozyme. Lei Zheng is a paid consultant/Advisory Board Member at Biosion, Alphamab, NovaRock, Akrevia, Datarevive, and Mingruzhiyao. Lei Zheng holds shares at Alphamab and Mingruzhiyao. Yanan Liu and Zaiqi Wang are employees of InxMed. Zaiqi Wang is a shareholder of InxMed. No potential conflicts of interest were disclosed by the other authors., (Copyright: © 2021, Cancer Biology & Medicine.)
- Published
- 2021
- Full Text
- View/download PDF
19. Corrigendum: Near-Single-Cell Proteomics Profiling of the Proximal Tubular and Glomerulus of the Normal Human Kidney.
- Author
-
Sigdel TK, Piehowski PD, Roy S, Liberto J, Hansen JR, Swensen AC, Zhao R, Zhu Y, Rashmi P, Schroeder A, Damm I, Sur S, Luo J, Yang Y, Qian WJ, and Sarwal MM
- Abstract
[This corrects the article DOI: 10.3389/fmed.2020.00499.]., (Copyright © 2021 Sigdel, Piehowski, Roy, Liberto, Hansen, Swensen, Zhao, Zhu, Rashmi, Schroeder, Damm, Sur, Luo, Yang, Qian and Sarwal.)
- Published
- 2021
- Full Text
- View/download PDF
20. Near-Single-Cell Proteomics Profiling of the Proximal Tubular and Glomerulus of the Normal Human Kidney.
- Author
-
Sigdel TK, Piehowski PD, Roy S, Liberto J, Hansen JR, Swensen AC, Zhao R, Zhu Y, Rashmi P, Schroeder A, Damm I, Sur S, Luo J, Yang Y, Qian WJ, and Sarwal MM
- Abstract
Molecular assessments at the single cell level can accelerate biological research by providing detailed assessments of cellular organization and tissue heterogeneity in both disease and health. The human kidney has complex multi-cellular states with varying functionality, much of which can now be completely harnessed with recent technological advances in tissue proteomics at a near single-cell level. We discuss the foundational steps in the first application of this mass spectrometry (MS) based proteomics method for analysis of sub-sections of the normal human kidney, as part of the Kidney Precision Medicine Project (KPMP). Using ~30-40 laser captured micro-dissected kidney cells, we identified more than 2,500 human proteins, with specificity to the proximal tubular (PT; n = 25 proteins) and glomerular (Glom; n = 67 proteins) regions of the kidney and their unique metabolic functions. This pilot study provides the roadmap for application of our near-single-cell proteomics workflow for analysis of other renal micro-compartments, on a larger scale, to unravel perturbations of renal sub-cellular function in the normal kidney as well as different etiologies of acute and chronic kidney disease., (Copyright © 2020 Sigdel, Piehowski, Roy, Liberto, Hansen, Swensen, Zhao, Zhu, Rashmi, Schroeder, Damm, Sur, Luo, Yang, Qian, Sarwal and the Kidney Precision Medicine Project (KPMP) Consortium.)
- Published
- 2020
- Full Text
- View/download PDF
21. Assessment of 19 Genes and Validation of CRM Gene Panel for Quantitative Transcriptional Analysis of Molecular Rejection and Inflammation in Archival Kidney Transplant Biopsies.
- Author
-
Sigdel T, Nguyen M, Liberto J, Dobi D, Junger H, Vincenti F, Laszik Z, and Sarwal MM
- Abstract
Background: There is an urgent need to develop and implement low cost, high-throughput standardized methods for routine molecular assessment of transplant biopsies. Given the vast archive of formalin-fixed and paraffin-embedded (FFPE) tissue blocks in transplant centers, a reliable protocol for utilizing this tissue bank for clinical validation of target molecules as predictors of graft outcome over time, would be of great value. Methods: We designed and optimized assays to quantify 19 target genes, including previously reported set of tissue common rejection module (tCRM) genes. We interrogated their performance for their clinical utility for detection of graft rejection and inflammation by analyzing gene expression microarrays analysis of 163 renal allograft biopsies, and subsequently validated in 40 independent FFPE archived kidney transplant biopsies at a single center. Results: A QPCR (Fluidigm) and a barcoded oligo-based (NanoString) gene expression platform were compared for evaluation of amplification of gene expression signal for 19 genes from degraded RNA extracted from FFPE biopsy sections by a set protocol. Increased expression of the selected 19 genes, that reflect a combination of specific cellular infiltrates (8/19 genes) and a graft inflammation score (11/19 genes which computes the tCRM score allowed for segregation of kidney transplant biopsies with stable allograft function and normal histology from those with histologically confirmed acute rejection (AR; p = 0.0022, QPCR; p = 0.0036, barcoded assay) and many cases of histological borderline inflammation (BL). Serial biopsy shaves used for gene expression were also processed for in-situ hybridization (ISH) for a subset of genes. ISH confirmed a high degree of correlation of signal amplification and tissue localization. Conclusions: Target gene expression amplification across a custom set of genes can identify AR independent of histology, and quantify inflammation from archival kidney transplant biopsy tissue, providing a new tool for clinical correlation and outcome analysis of kidney allografts, without the need for prospective kidney biopsy biobanking efforts., (Copyright © 2019 Sigdel, Nguyen, Liberto, Dobi, Junger, Vincenti, Laszik and Sarwal.)
- Published
- 2019
- Full Text
- View/download PDF
22. Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR.
- Author
-
Sigdel TK, Archila FA, Constantin T, Prins SA, Liberto J, Damm I, Towfighi P, Navarro S, Kirkizlar E, Demko ZP, Ryan A, Sigurjonsson S, Sarwal RD, Hseish SC, Chan-On C, Zimmermann B, Billings PR, Moshkevich S, and Sarwal MM
- Abstract
Standard noninvasive methods for detecting renal allograft rejection and injury have poor sensitivity and specificity. Plasma donor-derived cell-free DNA (dd-cfDNA) has been reported to accurately detect allograft rejection and injury in transplant recipients and shown to discriminate rejection from stable organ function in kidney transplant recipients. This study used a novel single nucleotide polymorphism (SNP)-based massively multiplexed PCR (mmPCR) methodology to measure dd-cfDNA in various types of renal transplant recipients for the detection of allograft rejection/injury without prior knowledge of donor genotypes. A total of 300 plasma samples (217 biopsy-matched: 38 with active rejection (AR), 72 borderline rejection (BL), 82 with stable allografts (STA), and 25 with other injury (OI)) were collected from 193 unique renal transplant patients; dd- cfDNA was processed by mmPCR targeting 13,392 SNPs. Median dd-cfDNA was significantly higher in samples with biopsy-proven AR (2.3%) versus BL (0.6%), OI (0.7%), and STA (0.4%) ( p < 0.0001 all comparisons). The SNP-based dd-cfDNA assay discriminated active from non-rejection status with an area under the curve (AUC) of 0.87, 88.7% sensitivity (95% CI, 77.7⁻99.8%) and 72.6% specificity (95% CI, 65.4⁻79.8%) at a prespecified cutoff (>1% dd-cfDNA). Of 13 patients with AR findings at a routine protocol biopsy six-months post transplantation, 12 (92%) were detected positive by dd-cfDNA. This SNP-based dd-cfDNA assay detected allograft rejection with superior performance compared with the current standard of care. These data support the feasibility of using this assay to detect disease prior to renal failure and optimize patient management in the case of allograft injury.
- Published
- 2018
- Full Text
- View/download PDF
23. Multiethnic meta-analysis identifies ancestry-specific and cross-ancestry loci for pulmonary function.
- Author
-
Wyss AB, Sofer T, Lee MK, Terzikhan N, Nguyen JN, Lahousse L, Latourelle JC, Smith AV, Bartz TM, Feitosa MF, Gao W, Ahluwalia TS, Tang W, Oldmeadow C, Duan Q, de Jong K, Wojczynski MK, Wang XQ, Noordam R, Hartwig FP, Jackson VE, Wang T, Obeidat M, Hobbs BD, Huan T, Gui H, Parker MM, Hu D, Mogil LS, Kichaev G, Jin J, Graff M, Harris TB, Kalhan R, Heckbert SR, Paternoster L, Burkart KM, Liu Y, Holliday EG, Wilson JG, Vonk JM, Sanders JL, Barr RG, de Mutsert R, Menezes AMB, Adams HHH, van den Berge M, Joehanes R, Levin AM, Liberto J, Launer LJ, Morrison AC, Sitlani CM, Celedón JC, Kritchevsky SB, Scott RJ, Christensen K, Rotter JI, Bonten TN, Wehrmeister FC, Bossé Y, Xiao S, Oh S, Franceschini N, Brody JA, Kaplan RC, Lohman K, McEvoy M, Province MA, Rosendaal FR, Taylor KD, Nickle DC, Williams LK, Burchard EG, Wheeler HE, Sin DD, Gudnason V, North KE, Fornage M, Psaty BM, Myers RH, O'Connor G, Hansen T, Laurie CC, Cassano PA, Sung J, Kim WJ, Attia JR, Lange L, Boezen HM, Thyagarajan B, Rich SS, Mook-Kanamori DO, Horta BL, Uitterlinden AG, Im HK, Cho MH, Brusselle GG, Gharib SA, Dupuis J, Manichaikul A, and London SJ
- Subjects
- Asian, Black People genetics, Female, Forced Expiratory Volume, Genetic Predisposition to Disease, Genomics, Hispanic or Latino, Humans, Male, Pulmonary Disease, Chronic Obstructive, Quantitative Trait Loci, Regression Analysis, Sample Size, Smoking, Vital Capacity, White People genetics, Genome-Wide Association Study, Linkage Disequilibrium, Lung physiology, Lung Diseases ethnology, Lung Diseases genetics, Polymorphism, Single Nucleotide
- Abstract
Nearly 100 loci have been identified for pulmonary function, almost exclusively in studies of European ancestry populations. We extend previous research by meta-analyzing genome-wide association studies of 1000 Genomes imputed variants in relation to pulmonary function in a multiethnic population of 90,715 individuals of European (N = 60,552), African (N = 8429), Asian (N = 9959), and Hispanic/Latino (N = 11,775) ethnicities. We identify over 50 additional loci at genome-wide significance in ancestry-specific or multiethnic meta-analyses. Using recent fine-mapping methods incorporating functional annotation, gene expression, and differences in linkage disequilibrium between ethnicities, we further shed light on potential causal variants and genes at known and newly identified loci. Several of the novel genes encode proteins with predicted or established drug targets, including KCNK2 and CDK12. Our study highlights the utility of multiethnic and integrative genomics approaches to extend existing knowledge of the genetics of lung function and clinical relevance of implicated loci.
- Published
- 2018
- Full Text
- View/download PDF
24. Whole-Genome Sequencing of Pharmacogenetic Drug Response in Racially Diverse Children with Asthma.
- Author
-
Mak ACY, White MJ, Eckalbar WL, Szpiech ZA, Oh SS, Pino-Yanes M, Hu D, Goddard P, Huntsman S, Galanter J, Wu AC, Himes BE, Germer S, Vogel JM, Bunting KL, Eng C, Salazar S, Keys KL, Liberto J, Nuckton TJ, Nguyen TA, Torgerson DG, Kwok PY, Levin AM, Celedón JC, Forno E, Hakonarson H, Sleiman PM, Dahlin A, Tantisira KG, Weiss ST, Serebrisky D, Brigino-Buenaventura E, Farber HJ, Meade K, Lenoir MA, Avila PC, Sen S, Thyne SM, Rodriguez-Cintron W, Winkler CA, Moreno-Estrada A, Sandoval K, Rodriguez-Santana JR, Kumar R, Williams LK, Ahituv N, Ziv E, Seibold MA, Darnell RB, Zaitlen N, Hernandez RD, and Burchard EG
- Subjects
- Adolescent, Black or African American genetics, Child, Female, Hispanic or Latino genetics, Humans, Male, Polymorphism, Single Nucleotide, United States, Albuterol therapeutic use, Asthma drug therapy, Bronchodilator Agents therapeutic use, Genome-Wide Association Study, Mexican Americans genetics, Pharmacogenomic Variants genetics, Race Factors
- Abstract
Rationale: Albuterol, a bronchodilator medication, is the first-line therapy for asthma worldwide. There are significant racial/ethnic differences in albuterol drug response., Objectives: To identify genetic variants important for bronchodilator drug response (BDR) in racially diverse children., Methods: We performed the first whole-genome sequencing pharmacogenetics study from 1,441 children with asthma from the tails of the BDR distribution to identify genetic association with BDR., Measurements and Main Results: We identified population-specific and shared genetic variants associated with BDR, including genome-wide significant (P < 3.53 × 10
-7 ) and suggestive (P < 7.06 × 10-6 ) loci near genes previously associated with lung capacity (DNAH5), immunity (NFKB1 and PLCB1), and β-adrenergic signaling (ADAMTS3 and COX18). Functional analyses of the BDR-associated SNP in NFKB1 revealed potential regulatory function in bronchial smooth muscle cells. The SNP is also an expression quantitative trait locus for a neighboring gene, SLC39A8. The lack of other asthma study populations with BDR and whole-genome sequencing data on minority children makes it impossible to perform replication of our rare variant associations. Minority underrepresentation also poses significant challenges to identify age-matched and population-matched cohorts of sufficient sample size for replication of our common variant findings., Conclusions: The lack of minority data, despite a collaboration of eight universities and 13 individual laboratories, highlights the urgent need for a dedicated national effort to prioritize diversity in research. Our study expands the understanding of pharmacogenetic analyses in racially/ethnically diverse populations and advances the foundation for precision medicine in at-risk and understudied minority populations.- Published
- 2018
- Full Text
- View/download PDF
25. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration.
- Author
-
Gordon AJ, Kavanagh G, Krumm M, Ramgopal R, Paidisetty S, Aghevli M, Goodman F, Trafton J, and Liberto J
- Subjects
- Health Services Needs and Demand, Humans, United States, United States Department of Veterans Affairs, Veterans Health, Attitude of Health Personnel, Buprenorphine therapeutic use, Health Services Accessibility, Narcotic Antagonists therapeutic use, Opioid-Related Disorders prevention & control
- Abstract
Opioid dependence is a chronic, relapsing disorder that deleteriously influences the health of those afflicted. Sublingual buprenorphine opioid agonist treatment (OAT) has been shown to be safe, effective, and cost-effective for the treatment of opioid dependence in nonspecialized, office-based settings, including the Veterans Health Administration (VHA). We sought to examine and describe provider-, facility-, and system-level barriers and facilitators to implementing buprenorphine therapy within the VHA. From June 2006 to October 2007, we conducted semistructured telephone interviews of key personnel at a national sample of VHA facilities with high prevalence of opioid dependence and without methadone OAT programs. Sites were categorized based on the number of veterans receiving buprenorphine prescriptions: More Buprenorphine (MB, >40 prescriptions, 5 sites), Some Buprenorphine (SB, 5-40 prescriptions, 3 sites), and No Buprenorphine (NB, 0-5 prescriptions, 9 sites). Interviews were taped, transcribed, and coded; consensus of coding themes was reached; and data were evaluated using grounded theory. Sixty-two staff members were interviewed. For NB sites, perceived patient barriers included lack of need and attitudes/stigma associated with opioid dependence. Provider barriers included lack of interest, stigma toward the population, and lack of education about buprenorphine-OAT. Prominent facilitators at MB sites included having established need, provider interest, and resources/time available for buprenorphine-OAT. The presence of a champion/role-model for buprenorphine care greatly facilitated its implementation. We conclude that factors that enable or impede buprenorphine-OAT vary by facility. Strategies and policies to encourage implementation of buprenorphine should be adaptable and target needs of each facility., ((PsycINFO Database Record (c) 2011 APA, all rights reserved).)
- Published
- 2011
- Full Text
- View/download PDF
26. Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals.
- Author
-
Kahn R, Biswas K, Childress AR, Shoptaw S, Fudala PJ, Gorgon L, Montoya I, Collins J, McSherry F, Li SH, Chiang N, Alathari H, Watson D, Liberto J, Beresford T, Stock C, Wallace C, Gruber V, and Elkashef A
- Subjects
- Adult, Behavior Therapy, Cocaine administration & dosage, Cocaine analogs & derivatives, Cocaine urine, Cocaine-Related Disorders rehabilitation, Cocaine-Related Disorders urine, Combined Modality Therapy, Counseling, Dose-Response Relationship, Drug, Double-Blind Method, Educational Status, Employment, Female, GABA Agonists therapeutic use, Humans, Limbic System drug effects, Limbic System physiopathology, Male, Middle Aged, Placebos, Racial Groups, Safety, Baclofen therapeutic use, Cocaine-Related Disorders drug therapy
- Abstract
Background: Cocaine dependence is a major public health problem for which there is no FDA-approved pharmacological treatment. Baclofen is a GABA(B) receptor agonist that in preclinical and early pilot clinical trials has shown promise for the treatment of cocaine dependence. The purpose of this multi-site, double-blind study, was to compare the safety and efficacy of baclofen (60 mg/day) vs placebo in an 8-week treatment of individuals with severe cocaine dependence. The primary outcome measure was subjects' self-reported cocaine use substantiated by urine benzoylecgonine (BE). Analysis of the data did not show a significant difference between the groups treated with baclofen and placebo. The current results do not support a role for 60 mg baclofen in treating cocaine dependence in the population studied. The contrast of this result to earlier, preclinical and human pilot data with baclofen may reflect the trial's focus on severe cocaine-dependent users, and/or the need for a higher baclofen dose. Baclofen's potential as a relapse prevention agent was not tested by the current design, but may be a useful target for future studies.
- Published
- 2009
- Full Text
- View/download PDF
27. Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration.
- Author
-
Gordon AJ, Liberto J, Granda S, Salmon-Cox S, Andree T, and McNicholas L
- Subjects
- Follow-Up Studies, Humans, United States, Veterans, Buprenorphine therapeutic use, Certification, Education, Health Occupations education, Narcotic Antagonists therapeutic use, Opioid-Related Disorders drug therapy, Practice Patterns, Physicians', United States Department of Veterans Affairs
- Abstract
Despite the high numbers of veterans with opioid dependence, few receive pharmacologic treatment for this disorder. The adoption of buprenorphine treatment within the Veterans Health Administration (VHA) has been slow. To expand capacity for buprenorphine treatment, the VHA sponsored two eight-hour credentialing courses for the Drug Addiction Treatment Act of 2000. We sought to describe the outcomes of such training. Following the training sessions, 29 participants (18 physicians) were highly satisfied with course content and affirmed their intention to prescribe buprenorphine; after nine-month follow-up, two physicians were prescribing. We conclude that providing credentialing courses, while popular, did not markedly promote the prescription of buprenorphine.
- Published
- 2008
- Full Text
- View/download PDF
28. Implementation of buprenorphine in the Veterans Health Administration: results of the first 3 years.
- Author
-
Gordon AJ, Trafton JA, Saxon AJ, Gifford AL, Goodman F, Calabrese VS, McNicholas L, and Liberto J
- Subjects
- Administration, Sublingual, Adult, Female, Humans, Male, Opioid-Related Disorders epidemiology, Treatment Outcome, United States epidemiology, United States Department of Veterans Affairs, Buprenorphine therapeutic use, Narcotic Antagonists therapeutic use, Opioid-Related Disorders rehabilitation, Veterans statistics & numerical data
- Abstract
Background: Compared to non-veterans, veterans are disproportionately diagnosed with opioid dependence. Sublingual buprenorphine provides greater access to opioid agonist therapy. To understand the diffusion of this innovative treatment within a large healthcare system, we describe the introduction of buprenorphine within the Veterans Health Administration (VHA) during the first 3 years of its approval as a VHA non-formulary medication., Methods: Using VHA pharmacy databases, we examined the number of physicians who have prescribed buprenorphine and the number of veterans who have received office-based buprenorphine within VHA veterans integrated service networks (VISN) from fiscal years (FY) 2003 through FY 2005 (October 2002 through September 2005)., Results: From FY2003 through FY2005 the number of veterans with opioid dependence increased from 25,031 to 26,859 (>7.3%) and the number of veterans prescribed office-based buprenorphine increased from 53 to 739. During this interval, 16 of 21 VISNs had prescribed buprenorphine. In FY2005, two VISNs accounted for 31% of buprenorphine prescriptions. The number of buprenorphine prescriptions varied widely by VISN, but increased from 212 to 7076 from FY2003 through FY2005. During this interval, prescriptions per patient increased from 4.0 to 9.6 and physicians prescribing buprenorphine increased from 14 to 170. The ratio of patients prescribed buprenorphine to providers prescribing buprenorphine increased from 3.8 to 4.3 with an average increase of 15.1-41.6 of prescriptions per provider., Conclusions: VHA increased, but not uniformly, the non-formulary use of office-based buprenorphine during the first 3 years of availability.
- Published
- 2007
- Full Text
- View/download PDF
29. The role of diagnostic systems in the continued stigmatization of patients with opioid dependence.
- Author
-
Welsh CJ, Cargiulo T, Gandhi DH, Liberto J, and Weintraub E
- Subjects
- Diagnostic and Statistical Manual of Mental Disorders, Humans, International Classification of Diseases, United States, Opioid-Related Disorders diagnosis, Stereotyping
- Published
- 2004
- Full Text
- View/download PDF
30. The use of medication for relapse prevention in substance dependence disorders.
- Author
-
Welsh CJ and Liberto J
- Abstract
Substance abuse is a significant problem in itself and can greatly complicate the symptomatology and treatment of comorbid psychiatric disorders. In the article, the authors review literature concerning the use of medication to prevent relapse to substance abuse or decrease substance use. Five different general strategies are employed for this purpose: 1) use of a drug with pharmacological properties similar to the substance of concern (i.e., agonist or substitution therapy); 2) use of a receptor antagonist to block or lessen the effects of the substance of concern; 3) use of a medication that produces a conditioned aversive reaction to the substance of concern; 4) use of a medication to reduce the reinforcing properties of the substance of concern; and 5) use of a substance to increase the metabolism or clearance of the substance of concern from the body. The authors review pharmacological treatments that have been studied for the treatment of dependence on the following types of substances: alcohol, sedative-hypnotics, opioids, stimulants, nicotine, hallucinogens, cannabis, inhalants, anabolic steroids, phencyclidine, and designer drugs. The article ends with a brief discussion of the importance of including psychosocial and behavioral interventions in any substance abuse treatment program.
- Published
- 2001
- Full Text
- View/download PDF
31. Naltrexone as an adjunctive treatment for older patients with alcohol dependence.
- Author
-
Oslin D, Liberto JG, O'Brien J, Krois S, and Norbeck J
- Subjects
- Aged, Alcoholism prevention & control, Double-Blind Method, Female, Humans, Male, Middle Aged, Patient Compliance, Recurrence, Severity of Illness Index, Alcoholism drug therapy, Naltrexone adverse effects, Narcotic Antagonists therapeutic use
- Abstract
The authors examined the efficacy of naltrexone as an adjunctive treatment for alcohol dependence in older adults. Forty-four veterans over 50 years of age were enrolled in a 12-week, double-blind, placebo-controlled efficacy study of naltrexone (the equivalent of 50 mg per day). There were no differences in the frequency of any self-reported adverse effects or in liver enzyme values between the placebo- and naltrexone-treated groups. There were no differences between the treatment groups in the number of subjects remaining abstinent or in the number of subjects who relapsed. However, all placebo-treated subjects relapsed after sampling alcohol, whereas only three of six naltrexone-treated subjects met relapse criteria after alcohol exposure (P = 0.024). The authors conclude that naltrexone was well tolerated and efficacious in preventing relapse in subjects who drank.
- Published
- 1997
- Full Text
- View/download PDF
32. Tolerability of naltrexone in treating older, alcohol-dependent patients.
- Author
-
Oslin D, Liberto JG, O'Brien J, and Krois S
- Subjects
- Age Factors, Anxiety chemically induced, Double-Blind Method, Female, Humans, Male, Middle Aged, Naltrexone adverse effects, Narcotic Antagonists adverse effects, Sleep drug effects, Alcoholism drug therapy, Naltrexone administration & dosage, Narcotic Antagonists administration & dosage
- Abstract
The authors conducted an interim analysis of the tolerability of naltrexone among older, alcohol-dependent adults. Thirty-six subjects over 50 years old were enrolled in a 12-week, double blind, placebo-controlled efficacy study of naltrexone. Sixteen subjects received naltrexone and were compared with the placebo group for the development of adverse effects. Self-reported adverse effects did not differ in frequency or duration between the placebo and naltrexone groups. There were no significant differences in laboratory values between the two groups. Naltrexone was well tolerated with no clinically significant adverse effects. However, the efficacy of naltrexone has yet to be determined in this age group.
- Published
- 1997
33. Early versus late onset of alcoholism in the elderly.
- Author
-
Liberto JG and Oslin DW
- Subjects
- Age Factors, Age of Onset, Aged, Alcoholism diagnosis, Alcoholism etiology, Female, Humans, Incidence, Male, Middle Aged, Prevalence, Social Support, United States, Alcoholism epidemiology
- Abstract
The age of onset of alcohol-related problems is a typology that is gaining prominence among clinicians. Findings from epidemiological studies suggest that there are a significant number of older alcoholics who first begin to drink alcohol "abusively" in their later years. While few demographic differences appear between late onset and early onset alcoholics, a number of studies have reported clinical differences between these groups that may affect the natural course and treatment outcome of the illness.
- Published
- 1995
- Full Text
- View/download PDF
34. Alcoholism in older persons: a review of the literature.
- Author
-
Liberto JG, Oslin DW, and Ruskin PE
- Subjects
- Aged, Alcoholism psychology, Alcoholism rehabilitation, Comorbidity, Cross-Sectional Studies, Humans, Incidence, Longitudinal Studies, Mental Disorders epidemiology, Mental Disorders psychology, Mental Disorders rehabilitation, United States epidemiology, Alcoholism epidemiology
- Abstract
Alcohol abuse and dependence in elderly persons is of growing social concern. The most consistent findings of cross-sectional and longitudinal studies are that the quantity and frequency of alcohol consumption is higher in elderly men than in elderly women, as is the prevalence of alcohol-related problems. Most studies show a decrease with age in consumption and alcohol-related problems among heavy drinkers. Longitudinal studies show no changes in consumption among light drinkers. Elderly persons with lower incomes consume less alcohol than those with higher incomes. Hospitalized and outpatient populations have more problem drinkers, and the elderly alcoholic is at greater risk for medical and psychiatric comorbidity. About one-third to one-half of elderly alcoholics experience the onset of problem drinking in middle or late life. Outcomes seem to be better for those who have late-onset drinking and may be improved for those treated in same-age rather than mixed-age groups.
- Published
- 1992
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.